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ABSTRACT OF DISSERTATION

ADDRESSING ASCERTAINMENT BIAS IN THE STUDY OF
CARDIOVASCULAR DISEASE BURDEN IN OPIOID USE DISORDERS
- APPLICATION OF NATURAL LANGUAGE PROCESSING OF
ELECTRONIC HEALTH RECORDS
In the United States, the prevalence of long-term exposure to opioid drugs, for both
medically and nonmedically indicated purposes, has increased considerably since the mid1990’s. Concerns have emerged about the potential health effects of opioid use. There is
also growing interest in other possible connections with opioid use including
cardiovascular disease. Electronic health records (EHR) contain information about patient
care in the form of structured codes and unstructured notes. Natural language processing
(NLP) provides a tool for processing unstructured textual data in EHR clinical notes and
extracts useful information for research with structured formats. The purpose of this
dissertation was to 1) to summarize peer-reviewed literature on the association between
non-acute opioid and cardiovascular disease (CVD) and identify the gap of this research
topic; 2) to apply NLP algorithm to estimate the extent of opioid use disorder (OUD)
among hospital inpatients that cannot be identified using ICD-10-CM codes; and 3) to
determine the extent to which estimates of the association between OUD and CVD may be
biased by misclassification of OUD cases that are not identifiable using ICD-10-CM codes.
First, we conducted a scoping review of the epidemiological literature on nonacute
opioid use and CVD. We summarized the current evidence about the association between
NOU and CVD, and identified some open questions on this topic. Then, we developed a
Natural Language Processing algorithm to identify cases of OUD in electronic healthcare
records that were not assigned an ICD-10-CM code for OUD by medical records coders,
but for which strong evidence of OUD exists in the unstructured clinical notes. Lastly, we
estimated the association between OUD and six types of CVD, arrythmia, myocardial
infarction, stroke, heart failure, ischemic heart disease, and infective endocarditis,
classifying OUD in two ways: defining OUD cases by ICD-10-CM codes alone, and using
a combination of cases identified by ICD-10-CM codes and cases identified using NLP
algorithm. We assessed the effect of misclassification of OUD status when using ICD-10CM codes alone.
KEYWORDS: Opioid use disorder, Cardiovascular disease, Natural language processing,
electronic healthcare records
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CHAPTER 1. INTRODUCTION
Exposure to opioid drugs among United States (U.S.) residents has increased
exponentially over the past 30 years (Hedegaard et al., 2018). This includes the use of
prescription opioids for medical purposes, as directed by a physician – such as for
treatment of opioid dependence, cancer-related pain, or noncancer chronic pain – as well
as non-medically indicated use of both prescription and illicit opioids. A major driver of
increasing opioid use was the perception of under-treatment of pain (Bernard et al., 2018;
Meldrum, 2016). Initially, opioid treatment was restricted to cancer-related pain and then
later expanded to non-cancer related pain. As a result, opioid prescribing in the U.S.
increased nearly seven-fold between 1997 and 2007, from 100 to nearly 700 morphine
milligram equivalents per capita (Paulozzi et al., 2011). This increase in opioid availability
was accompanied by steep increases in fatal and nonfatal overdoses and an increase in the
prevalence of opioid use disorders (OUD) (Haight et al., 2018; Martins et al., 2017).
Intravenous use of both prescription and illicit opioids has contributed to outbreaks of
infectious diseases including HIV, hepatitis, and infective endocarditis (National
Academies of Sciences and Medicine 2020).
Opioid use disorder is a chronic relapsing disorder that increasingly engages antireward neurocircuits that drive adverse emotional states and relapse (Strang et al., 2020).
Several consequences of OUD cause substantial burden to the individual, their family and
the community. For example, OUD itself carries a substantial health burden owing to the
disability associated with OUD and the risk of over-dose. People who developed OUD
have an increased risk of different health issues, for example, injuries, suicide, homicide,
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blood-borne virus infections compared to the general population (Larney, 2020 ; Maloney,
2007; Pierce, 2015; Suryaprasad, 2014; Volkow, 2016; Zibbell, 2015).
In recent years, concerns have emerged about possible cardiovascular effects of
opioid use. The risk of infective endocarditis associated with injection drug (including
opioid) use has been well-documented (Behzadi et al., 2018; Mihm et al., 2020; Sinner et
al., 2021) and they published a review on the relationship between opioid use and cardiac
arrhythmia. The authors reported that methadone posed a high risk of QT interval
prolongation and arrhythmogenicity, even at low doses. A small number of studies have
documented a positive association between opioid exposure and the risk of acute
myocardial infarction (MI) (Carman et al., 2011; Jobski et al., 2017; Li et al., 2013;
Roberto et al., 2015). Given the high prevalence of opioid use in the U.S. population, even
a relatively small effect of opioids on the risk of cardiovascular disease (CVD) would have
significant public health implications.
Research on the possible cardiovascular effects of long-term opioid use presents
many challenges. Randomized trials would clearly be unethical. CVD has a long latency
period. Exposure to prescription opioids for medical purposes would be difficult enough
to measure accurately over a such a long period of time, not to mention nonmedical use of
prescription and illicit opioids.
One approach is to leverage administrative hospital records to identify the burden
of CVD in association with opioid drug use. Both OUD and cardiovascular conditions can
be identified in these data sources using International Classification of Diseases (ICD)
codes, which are commonly used for this purpose due to their widespread use in medical
record coding and their accessibility to researchers (Beam et al., 2021; Mezzich, 2002).
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The limitations of ICD codes, including low sensitivity and specificity for many
conditions, have been well-documented (Hughes Garza et al., 2021; Kurbasic et al., 2008;
O'Malley et al., 2005; Quan et al., 2008), although there has been little investigation of the
extent to which this may be true for OUD. If ICD codes have low sensitivity to identify
OUD when it is present, then many patients with OUD would be misclassified, in this type
of study, as not having OUD. This could result in biased estimates of the association
between OUD and CVD.
Electronic health records (EHR) contain – in addition to structured ICD codes –
substantial information about patient care in the form of unstructured, narrative text
entered by providers, nurse, lab technician or any other member of patient’s healthcare
team (Spasic and Nenadic, 2020). These clinical notes include information on patient
symptoms, conditions, behaviors, and healthcare advice and plans (Wang et al., 2018).
Generally, information in unstructured notes includes demographics, medical encounters,
developmental history, obstetric history, medications and medical allergies, family history,
social history, habits, immunization records (Gliklich et al., 2019).
Natural language processing (NLP) provides a tool for processing unstructured
textual data in EHR clinical notes. (Pendergrass and Crawford, 2019). Information
extraction is a subtask of NLP that is focused on the extraction of structured data from text
(Ford et al., 2016; Meystre et al., 2008). Typically, information extraction involves
splitting text into basic units called tokens, which are individual words, punctuation marks,
etc. (Ford et al., 2016). Rule-based approaches to information extraction attempt to identify
matches of pre-specified sequences of tokens (Nadkarni et al., 2011). Statistical
approaches rely on probabilistic models, or on supervised learning methods applied to very
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large corpuses of text that have been labeled to indicate which instances do, and which do
not, contain the information of interest (Carrell et al., 2015). In supervised learning
approaches, systems can be trained to recognize entities within text documents by seeing
many correctly-labelled examples and “learning” features of the text that accurately
predict the presence of those entities (Spasic and Nenadic, 2020). Although powerful, a
limitation of this approach is the enormous effort required to create a sufficiently large,
prelabeled corpus of examples (Nadkarni et al., 2011; Velupillai et al., 2018).
Whereas NLP has been successfully applied to EHR records to extract information
on certain disease conditions, including cancer and diabetes, there has been little previous
work on OUD (Sheikhalishahi et al., 2019; Wang et al., 2018). Carrell et al (2015)
investigated the potential to apply NLP to EHR records to increase the identification of
problem use of prescription opioids (POU) among patients undergoing chronic opioid
therapy. POU was defined as indications of addiction, abuse, misuse or overuse, and is
thus more broadly defined and less specific than OUD. Using NLP methods, Carrell et al
identified 33% more cases of POU than could be identified by ICD-9-CM codes alone
(Carrell et al., 2015).
There is an opportunity to utilize NLP methods to answer important questions about
the sensitivity of ICD codes in the identification of OUD from administrative hospital data
sources, and the effect on research into the association between OUD and CVD.
The aims of this dissertation were 1) to summarize peer-reviewed literature on the
association between non-acute opioid use and CVD; 2) to use NLP methods to estimate
the extent of OUD among hospital inpatients that cannot be identified using ICD codes;
and 3) to determine the extent to which estimates of the association between OUD and
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CVD may be biased by misclassification of OUD cases that are not identifiable using ICD
codes.
Chapter Two represents a scoping review of the epidemiological literature on
nonacute opioid use (Kivimaki et al.) and CVD, summarizing the current evidence about
the association between NOU and CVD, and identifying open questions on this topic. In
Chapter Three, we develop a Natural Language Processing (NLP) pipeline for identifying
cases of OUD in electronic patient records that were not assigned an ICD-10-CM code for
OUD by medical records coders, but for which strong evidence of OUD exists in the
unstructured clinical notes. In Chapter Four, we estimate the association between OUD
and six types of CVD. We classify OUD in two ways: using ICD codes alone, and using a
combination of ICD codes and cases of OUD identified using NLP. We assess the effect
of misclassification of OUD status using ICD codes alone. Chapter Five presents an
integrative summary of our findings.
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CHAPTER 2.

ASSOCIATION OF NONACUTE OPIOID USE AND

CARDIOVASCULAR DISEASES: A SCOPING REVIEW OF THE LITERATURE

2.1

Abstract
In this scoping review, we identified and reviewed twenty-three original articles

from the PubMed database that investigated the relationship between nonacute opioid use
(Kivimaki et al.) and cardiovascular outcomes. We defined NOU to include both long-term
opioid therapy and opioid use disorder. We summarized the association between NOU and
five classes of cardiovascular disease (CVD), including infective endocarditis, coronary
heart disease (including myocardial infarction), congestive heart failure, cardiac arrythmia
(including cardiac arrest), and stroke. The most commonly studied outcomes were coronary
heart disease and infective endocarditis. There was generally consistent evidence of a
positive association between community prevalence of injection drug use (with opioids
being the most commonly injected type of drug) and community prevalence of IE, and
between (primarily medically indicated) NOU and MI. There was less consensus about the
relationship between NOU and CHF, cardiac arrhythmia, and stroke. There is a dearth of
high-quality evidence on the relationship between NOU and CVD. Innovative approaches
to the assessment of opioid exposure over extended periods of time will be required to
address this need.

2.2

Background
Exposure to opioid drugs in the United States (U.S.) has increased exponentially

over the past 30 years (Haight et al., 2018; Hedegaard et al., 2018; Porter and Jick, 1980;
Singh and Cleveland, 2020). This includes use of prescription opioids for medical purposes
as directed by a physician – such as, treatment of opioid dependence, cancer-related pain,

or non-cancer chronic pain – as well as non-medically indicated use of prescription opioids
and illicit opioid use. Opioid treatment, initially restricted to cancer patients, expanded over
time to include the treatment of non-cancer related pain. A growing awareness of the
problem of undertreated pain resulted in standards, issued by the Joint Commission on
Accreditation of Healthcare Organizations in 2001, requiring greater monitoring and
treatment of pain (Max, 1990; Phillips, 2000). Pharmaceutical companies aggressively
marketed opioid medications for treatment of chronic pain (Maxwell, 2011), citing flawed
research studies as evidence of the safety of these medications (Portenoy and Foley, 1986).
As a result of these and other factors, opioid prescribing in the U.S. increased nearly sevenfold between 1997 and 2007. The increase in opioid availability was accompanied by steep
increases in fatal and nonfatal overdoses (Paulozzi et al., 2011) and opioid use disorder
(OUD) (Haight et al., 2018; Martins et al., 2017).
Long-term opioid therapy – such as for the treatment of chronic pain or opioid
addiction – has been defined as use of opioids on most days for more than 3 months
(Dowell et al., 2016). Long-term exposure to opioids may also result from the nonmedical
use of prescription or illicit opioids due to dependence or addiction, leading to an opioid
use disorder (OUD). We use the term “nonacute opioid use” (Kivimaki et al.) to encompass
both long-term opioid therapy and OUD.
Researchers have begun to investigate possible effects of long-term opioid use on
health outcomes other than addiction and misuse. Of specific interest is cardiovascular
disease, which remains a leading cause of death, physician and emergency department
visits, and hospitalization in the United States (Geidrimiene and King, 2017; Mensah and
Brown, 2007). Trends in hospitalized cases of infective endocarditis (Beck, 2019) have
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been shown to mirror trends in opioid overdose and injection drug use (National Academies
of Sciences and Medicine, 2020). Observational studies have also reported an association
of opioid drug use with increased risk of cardiovascular events, including MI and heart
failure.
However, it is unclear what the biological pathways between long-term exposure
to opioids and CVD might be. Opioid receptors have been discovered in the heart, and their
activation by short-term administration of opioid drugs prior to acute ischemic events has
been shown to have a cardioprotective effect (Schultz and Gross, 2001). However, the
association between chronic opium use and increased levels of low-density lipoproteins
and triglycerides could provide a pathway to coronary artery disease (Aghadavoudi et al.,
2015; Zagaria, 2018). High and increasing prevalence of NOU and a sustained high burden
of cardiovascular disease have prompted this scoping review of the literature to
systematically examine the association of NOU with cardiovascular outcomes.

2.3

Methods
We identified original, peer-reviewed research articles on the relationship between

NOU involving any prescription medication containing opioids, or any illicit opioid drug,
and cardiovascular disease (CVD). We conducted a keyword search and a MeSH term
search of the PubMed database for articles published on or before September 2, 2019. The
keyword search included the following strings and logic: (("Heart Failure" OR
Endocarditis OR "Myocardial infarction" OR "Atrial fibrillation" OR "cardiac arrhythmia"
OR "myocardial ischemia" or "coronary heart disease" or "cardiac arrest" or “stroke” or
"coronary artery disease")) AND Opioid AND epidemiology. For the MeSH term search,
the strings and logic were: (("Analgesics, Opioid"[Majr] OR "Opioid-Related
8

Disorders/epidemiology"[Majr]) AND ("Cardiovascular Diseases/epidemiology"[Majr]
OR “Stroke/epidemiology” [Majr])). We included the term “epidemiology” in both key
word and MeSH term searches to exclude basic science and non-human studies. Additional
articles were identified from the reference lists of retrieved articles.

2.3.1

Inclusion and exclusion criteria
We included original articles that investigated the association of NOU with one or

more of the following five cardiovascular outcomes: infective endocarditis (IE); coronary
heart disease, including myocardial infarction (MI); congestive heart failure (CHF); cardiac
arrythmia, including cardiac arrest; and stroke. We excluded studies that lacked an
appropriate comparison group. In most cases, this meant individuals who did not
experience NOU. In the case of endocarditis, it meant either individuals who did not inject
opioids, or a time period during which injection opioid use was expected to be substantially
lower due to a policy change. The details of inclusion and exclusion are listed in Table 2.1.
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Table 2. 1 Inclusion and exclusion criteria for studies
Inclusion Criteria

Exclusion Criteria

• Investigates the relationship
between a history of long-term
(medical or nonmedical) exposure
to opioids (prescription or illicit)
and subsequent cardiovascular
disease
• Investigates the relationship
between history of opioid use and
cardiovascular outcomes
following a (not necessarily
cardiovascular) medical procedure
(e.g. kidney transplant, orthopedic
surgery, etc.)

• Basic science studies
• Non-human studies
• Case study or case series
• Review articles
• Non-original research including editorials,
letters and protocols
• Short term opioid use
• Studies of the effect of brief exposures to opioid
medications (e.g. for analgesia or anesthesia
related to a surgical procedure or other medical
events)
• Studies of the relationship between opioid use
and any cardiovascular events other than those
of interest

One author (JS) reviewed the entire list of identified references, while two authors
(AKN and ELA) each reviewed a mutually exclusive half of the references. Disagreement
in the classification of records by the two independent reviewers was adjudicated by group
consensus. A flow diagram summarizes article selection procedures (Figure 2.1).
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Figure 2. 1 Flow diagram of included studies

11

2.4

Results
A total of 39 articles were identified from the MeSH term search and 294 articles

from the keyword search. After excluding reviews and case series, articles that did not
address NOU or any of our outcomes of interest, those that did not include a comparison
group, and those for which full text could not be retrieved; and after and resolving
duplicates that were retrieved through both search protocols, 23 studies remained for
review. Fourteen articles were from the U.S., 2 from Iran, 2 from Canada and 1 each from
of the following countries: United Kingdom, Italy, Germany, Spain, Taiwan. There were
10 cohort studies (Carman et al., 2011; Jain et al., 2008; Keeshin and Feinberg, 2016;
Lentine et al., 2015; Marmor et al., 2004; Meisner et al., 2019; Menendez et al., 2015;
Mirzaiepour, 2012; Omran et al., 2019; Solomon et al., 2010), 5 case-control (Jobski et al.,
2017; Lee et al., 2013; Li et al., 2013; Porter and Jick, 1980; Roberto et al., 2015), 3 crosssectional (Khodneva et al., 2016; Sadeghian et al., 2009; Vozoris et al., 2017), and 5 trend
analyses (Bates et al., 2019; Gray et al., 2018; Hartman et al., 2016; Lewer et al., 2017;
Weir et al., 2019) (Table 2). All included studies utilized retrospective designs.
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Table 2. 2. Selected major studies of the association of nonacute opioid use with Endocarditis, MI, CHF, Arrhythmia, and Stroke

Study
Bates, 2019(Bates
et al., 2019),
United States
Carman,
2011(Carman et
al., 2011),
United States

Gray, 2018(Gray
et al., 2018),
United States
Hartman,
2016(Hartman et
al., 2016),
United States
Jain, 2008(Jain et
al., 2008),
United States

Study
Year frame
design

N

Exposure

Outcome

Effect Estimate

RTA

2008-2015

462

Illicit drug use

Endocarditis

Relative Risk increase =
0.06%, P=0.001

RCS

2002-2005

148,657

Overall chronic opioid I therapy
for non-malignant pain

Myocardial
infarction

IRR = 2.66, 95% CI 2.3 - 3.08

Low dose chronic opioid
therapy for non-malignant pain

Myocardial
infarction

IRR = 1.21, 95% CI 1.02 1.45

High dose chronic opioid
therapy for non-malignant pain

Myocardial
infarction

Injection drug use
(no mention of opioid name)

Endocarditis

IRR = 1.89, 95% CI 1.54 2.33
Prevalence ratio of IDU per
year = 1.09, 95% CI: 1.05–
1.14

RTA

2000-2016

510

II

RTA

2009-2014

127

Injection drug use

RCS

1996-2003

238

Injection drug use III
Injection drug use
Heroin

CC

2006-2011

309,936

Endocarditis
Tricuspid valve
(TV) IE
mitral valve (MV)
IE
Tricuspid valve
(TV) IE

Percentage of endocarditis
increases from 14% in 2009 to
56% in 2014
OR 4.37, p=0.001
OR 4.37, p=0.001
OR 4.37, p=0.001
OR = 1.17,

Jobski, 2017
(Jobski et al.,
2017),
Germany

Keeshin, 2016
(Keeshin and
Feinberg, 2016),
United States

RCS

1999-2009

392

Current or recent use of ERHPOIV (referent: past use)
Recent discontinuation of any
ER-HPO (referent: past use)
Recent switch of substance
(referent: past use)
Current or recent use of ERHPO (referent: past use)
Recent discontinuation of any
ER-HPO (referent: past use)
Recent switch of substance
(referent: past use)

Myocardial
infarction
Myocardial
infarction
Myocardial
infarction

OR = 1.11, 95% CI 0.98 - 1.25

Stroke

OR = 0.95, 95% CI 0.88 - 1.02

Stroke

OR = 1.14, 95% CI 1.02 - 1.27

Stroke

OR = 1.19, 95% CI 0.89 - 1.58

Injection opioid use V

Endocarditis

Endocarditis cases increase 2fold

HCV antibody
prevalence
Positive opiate
toxicology screens

HCV antibody prevalence
increase 3-fold
Positive opiate toxicology
screens increase 6-fold

Injection opioid use
Injection opioid use

Khodneva, 2016
(Khodneva et al.,
2016),
United States

Lee, 2013(Lee et
al., 2013),

CS

CC

2003-2007

1998-2010

29,025

6,040

Prescription opioid VI use for
Stroke
nonmalignant chronic pain
Prescription opioid use for
Coronary artery
nonmalignant chronic pain
disease in all
Prescription opioid use for
Coronary artery
nonmalignant chronic pain
disease in female
Prescription opioid use for
Coronary artery
nonmalignant chronic pain
disease in male
Treatment with morphine for all
Stroke: All stroke
cancer-related pain
14

95% CI 1.09 - 1.26

OR = 1.38, 95% CI 1.02 - 1.86

HR = 1.04, 95% CI 0.78 - 1.38
HR = 1.03, 95% CI 0.83 - 1.26
HR = 1.38, 95% CI 1.05 - 1.82
HR = 0.7, 95% CI 0.5 - 0.97
OR = 1.13, 95% CI 0.97 - 1.31

Taiwan

Treatment with morphine for
prostate cancer-related pain
Treatment with morphine for
prostate cancer-related pain
Treatment with morphine for
prostate cancer-related pain
RCS

2006-2008

16,322

Lentine, 2015
(Lentine et al.,
2015),
United States

Lewer, 2017
(Lewer et al.,
2017),
UK
Li, 2013(Li et al.,
2013),
United States

Stroke:
Hemorrhagic

OR = 4.24, 95% CI 1.03 - 17.4

Stroke: Ischemic

OR = 2.9, 95% CI 1.58 - 5.35

Ventricular
arrhythmia

HR = 1.38, 95% CI 0.14 13.42

Ventricular
arrhythmia

HR = 5.58, 95% CI 2.19 14.21

Cardiac arrest

HR = 1.83, 95% CI 0.94 - 3.54

Cardiac arrest

HR = 1.31, 95% CI 0.85 - 2.01

Injection opioid use

Endocarditis

Hospital admissions for
infections related to injection
drug use increased annually
from 2012 to 2016.

Any opioid prescription VII at
current use (<=30 days)
Any opioid prescription
cumulative use 11 to 50 Rx
Any opioid prescription
cumulative use > 50 Rx

Myocardial
infarction
Myocardial
infarction
Myocardial
infarction
Myocardial
infarction

Pre-transplant prescription
narcotic use with living donor
Pre-transplant prescription
narcotic use with deceased
donor
Pre-transplant prescription
narcotic use with living donor
Pre-transplant prescription
narcotic use with deceases
donor

RTA

CC

1997-2016 1,052,444

1990-2008

56,590

Stroke: All stroke OR = 3.02, 95% CI 1.68 - 5.42

Buprenorphine prescription
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OR = 1.28, 95% CI 1.19 - 1.37
OR = 1.38, 95% CI 1.28 - 1.49
OR = 1.25, 95% CI 1.11 - 1.4
OR = 1.71, 95% CI 1.09 - 2.68

Morphine prescription
Meperidine prescription
Marmor, 2004
(Marmor et al.,
2004),
United States
Meisner,
2019(Meisner et
al., 2019),
United States
Menendez, 2015
(Menendez et al.,
2015),
United States
Mirzaiepour,
2012
(Mirzaiepour,
2012), Iran
Omran, 2019
(Omran et al.,
2019),
United States

Pontes,
2018(Porter and
Jick, 1980),

Myocardial
infarction
Myocardial
infarction

OR = 2.15, 95% CI 1.24 - 3.74
OR = 1.46, 95% CI 1.22 - 1.76

RCS

1998

98

Serologic evidence of
methadone or opiates (as proxy
for long-term exposure to
opioids)

RCS

2013-2017

1,921

Injection drug use

Endocarditis

Endocarditis percentage
change = 238%

RCS

2002-2011 9,307,348

Opioid use disorder (opioid
abuse or dependence)

Myocardial
infarction

OR = 1.9, 95% CI 1.3 - 2.6

RCS

2010-2011

Opium addiction (as defined by
DSM-IV criteria for substance
dependence)

Arrhythmia and
cardiac arrest

OR = 21.9, 95% CI 9.58 50.01

RCS

1993-2015

200

5,283

Opioid

Coronary artery
disease

OR = 0.43, 95% CI 0.2 - 0.94

Stroke

Stroke

CC

2008-2012

22,652

Opioid analgesic therapy for
OA-related pain
16

Myocardial
infarction

Stroke percentage change from
1993 to 2008
= 1.9%, 95% CI -2.2% - 6.1%
PCT change from 2008 to
2015
= 20.3%, 95% CI 10.5% 30.9%
OR = 1.13, 95% CI 1.03 - 1.24

Spain

Roberto,
2015(Roberto et
al., 2015),
Italy

CC

2002-2012

12,483

Current use of acetaminophen
or/and an acetaminophencodeine combination (0-90
days) (referent = nonuse,
defined as more than 365 days
since last use)

OR = 1.13, 95% CI 0.86 - 1.48

Opioid dependence (according
to DSM-IV criteria)
Opioid dependence (according
to DSM-IV criteria)

Arrhythmia and
cardiac arrest

RR = 0.65, 95% CI 0.43 - 1.03

Past use

Solomon,
2010(Solomon et
al., 2010),
United States
Vozoris, 2017
(Vozoris et al.,
2017),
Canada

CS

2006-2008

4,398

OR = 1.22, 95% CI 0.92 - 1.63

Myocardial
infarction
Myocardial
infarction
Myocardial
infarction

Recent use

Sadeghian, 2009
(Sadeghian et al.,
2009),
Iran

Myocardial
infarction

OR = 1.12, 95% CI 0.8 - 1.55

RR = 0.34, 95% CI 0.02 - 3.23

RCS

1996-2005

31,375

Incident opioid therapy VIII for
nonmalignant pain

Nonspecific

RR = 1.62, 95% CI 1.27 - 2.06

CS

2008-2013

149,094

Incident opioid use IX

Heart failure

HR = 0.84, 95% CI 0.73 - 0.97

Incident opioid use

Coronary artery
disease

HR = 2.15, 95% CI 1.5 - 3.09
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Weir, 2019(Weir
et al., 2019),
Canada

RTA

2006-2015

60,529

Intervention: removal of
controlled-release oxycodone
from Canadian market (2011
Q4)

18

Endocarditis

No quantitative estimates
provided

Abbreviations in Table 2.2:
CC: Case control;
CS: Cross sectional;
RCS: Retrospective cohort study;
RTA: Retrospective trend analysis;
TV: Tricuspid valve;
MV: Mitral valve;
IRR: Incidence rate ratios;
OR: Odds Ratio;
RR: Relative risk;
HR: Hazard ratio;
Cl: Confidence Interval;
HCV: Hepatitis C virus;
ER-HPO: Extended-release high-potency opioid;
PCT: Percentage;
DSM-IV: Diagnostic and Statistical Manual - 4.

Notes: Opioid names listed in Exposure in Table 2 with roman numerals are listed in
Supplemental Table 1.

2.4.1

Myocardial infarction (MI)
Of the 10 studies that reported on the association of opioid use with MI, four used

data from retrospective cohorts (Carman et al., 2011; Khodneva et al., 2016; Sadeghian et
al., 2009; Vozoris et al., 2017) , 2 were cross-sectional (Marmor et al., 2004; Menendez
et al., 2015) , and 4 were nested case-control studies (Jobski et al., 2017; Li et al., 2013;
Porter and Jick, 1980; Roberto et al., 2015). Among older adults with chronic obstructive
pulmonary disease, when restricting to opioid-only formulation, positive associations
were observed for CAD-related mortality: HR=1.83, 95% CI (1.32-2.53), and for CADrelated ER visit or hospital admission: HR=1.38, 95% CI (1.08-1.77). Carman et al.
reported a positive association between chronic opioid therapy for nonmalignant pain and
MI incidence in a commercially insured cohort, with greater risk observed at higher doses
[Incidence Rate Ratio (IRR) = 2.66, 95% CI (2.30-3.08)]. Within a group of patients who
underwent coronary artery bypass (CABG) (Sadeghian et al., 2009), a relative risk of
0.34 [95% CI (0.02-2.32)], was reported for perioperative MI, among patients with
preoperative opioid dependence. However, the extremely wide CI indicates the
possibility of a sparse data bias.
In a case-control study of primary care patients with physician-diagnosed
osteoarthritis (Baclic et al., 2020), Pontes et al. reported a positive association between
the odds of MI and use of opioid analgesics for treatment of OA [OR=1.13, 95% CI
(1.03-1.24)], with odds increasing as the mean monthly dose of opioids increased. Jobski
et al. reported associations with recent (within 30 days of index MI) discontinuation of
extended-release high-potency opioid (ER-HPO) therapy [OR=1.11, 95% CI (0.98-1.25)]
and recent (within 30 days of index MI) switch [OR=1.38, 95% CI (1.02-1.86)] of ER-
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HPO medication type (Jobski et al., 2017). Within a group of general practice patients
with OA, Roberto et al. reported no statistically significant association with
acetaminophen-codeine for treatment of OA pain [OR=1.22, 95% CI (0.92-1.63)]
(Roberto et al., 2015). Li et al. 31 reported a positive association between MI and current
opioid use [OR=1.28, 95% CI (1.19-1.37)], two-year cumulative prior use consisting of
11 to 50 prescriptions [OR=1.38, 95% CI (1.28-1.49)], and two-year cumulative prior use
consisting of more than 50 prescriptions [OR=1.25, 95% CI (1.11-1.40)] (Li et al., 2013).
Findings from Marmor’s cross-sectional study of serological evidence of
methadone or opioid use at autopsy, and its relationship to coronary artery plaque,
suggest a protective effect with respect to CAD [OR 0.43, 95% CI (0.20-0.94)] (Marmor
et al., 2004). However, the study did not provide information on duration of opioid use or
of methadone treatment of opioid addiction. Among hospital in-patients undergoing
major elective orthopedic surgery, Menendez et al. reported a positive association
between preoperative opioid abuse or dependence and in-hospital MI [OR=1.90, 95% CI
(1.30-2.60)] (Menendez et al., 2015).
Conversely, data from the REGARDS study suggest no association overall
between prescription opioid use for nonmalignant chronic pain and coronary heart
disease (CHD) over the course of four to seven years of follow-up [HR=1.03, 95% CI
(0.83-1.26)]. In an analysis stratified by gender, the authors report a modest increase in
CHD risk among women [HR=1.38, 95% CI (1.05-1.82)], but a decrease in risk among
men [HR 0.70, 95% CI (0.50-0.97)] with evidence of opioid use (Khodneva et al., 2016).
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2.4.2

Heart failure
There were no studies of NOU and heart failure identified in our search.

2.4.3

Arrhythmia
Of the three studies that reported on the association of opioid use with arrhythmia,

two used data from retrospective cohorts (Lentine et al., 2015; Sadeghian et al., 2009)
and one was a cross-sectional study (Mirzaiepour, 2012). In a cohort of hospital patients
who underwent CABG surgery, Sadeghian et al. reported a protective association
between atrial fibrillation and opium addiction that was not statistically significant
[OR=0.65, 95% CI (0.43-1.03)] (Sadeghian et al., 2009). In hospital patients admitted
with acute MI, Mirzaiepour et al. reported a strong, positive association between post-MI
arrhythmia and opium addiction [OR=21.9, 95% CI (9.58-50.0)] (Mirzaiepour, 2012). In
a cohort of kidney transplant patients, Lentine et al. reported a positive association
between ventricular arrhythmia and pre-transplant opioid use at a dose greater than 23.8
mg/kg morphine equivalents [HR=5.58, 95% CI (2.19-14.21)] (Lentine et al., 2015).

2.4.4

Stroke
Of the four studies reporting on the association of opioid use and ischemic or

hemorrhagic stroke, two used data from a retrospective cohort (Khodneva et al., 2016;
Omran et al., 2019) and two were nested case-control studies (Jobski et al., 2017; Li et
al., 2013). Jobski et al. reported an association with recent (within 30 days of index MI)
discontinuation of extended-release high-potency opioid therapy [OR=1.14, 95% CI
(1.02-1.27)] (Jobski et al., 2017). No association was reported for current opioid use or
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recent switch of opioid type. Omran et al. reported percentage of stroke among
hospitalization changed 20.3% [95% CI 10.5% - 30.9%] from 2008 to 2015 with the
combination of opioid abuse (Omran et al., 2019). Khodneva et al. reported no
association between prescription opioid use for nonmalignant chronic pain and stroke
over the course of median 42 of 5.2 (1.8) years of follow-up in the REGARDS study
[HR=1.04, 95% CI (0.78-1.38)] (Khodneva et al., 2016). Lee et al. reported a positive
association between morphine use for cancer-related pain and hemorrhagic stroke
[OR=1.36, 95% CI (1.02-1.82)] but not ischemic stroke [OR=1.08, 95% CI (0.92-1.27)]
(Lee et al., 2014). When restricting to prostate cancer patients only, the association with
hemorrhagic stroke was higher [OR=4.24, 95% CI (1.03-17.4)], and a significant
association with ischemic stroke was reported [OR=2.90, 95% CI (1.58-5.35)].

2.4.5

Infective endocarditis
Seven studies investigated the association between opioid use and infective

endocarditis (IE). Five of these were trend analyses, of which four reported a temporal
association between injection drug use (IDU) and IE (Gray et al., 2018; Hartman et al.,
2016; Lewer et al., 2017; Meisner et al., 2019; Weir et al., 2019), and one reported a
temporal association between mixed drug use and IE (Jain et al., 2008). Jain and
colleagues reported an association between IDU and tricuspid valve IE (Jain et al., 2008).
Keeshin and colleagues suggested that increases in hospital admissions for IE may
provide an indirect surveillance marker for IDU within the surrounding community
(Keeshin and Feinberg, 2016).

23

2.5

Discussion
There has been a growing interest in the possible cardiovascular effects of opioid

drugs. Khodneva et al. described self-reported, baseline cardiovascular disease (CVD) in
a cohort of community-dwelling adults consisting of 1,851 participants with prescription
opioid use 26 and 27,174 nonusers (Khodneva et al., 2016). They found that coronary
heart disease (22.8% vs. 17.4%), stroke (13.2% vs. 8.5%) and QTc prolongation (3.3%
vs. 2.8%) were more commonly reported by participants with POU. Studies have
investigated the link between methadone treatment for OUD and elongation of the QT
interval/torsade de pointes (TdP), which can lead to cardiac arrhythmias and cardiac
arrest (Barkin et al., 2006; Keller et al., 2016b). Solomon et al. reported different relative
risk of cardiac events after the start of different opioid therapy(Solomon et al., 2010).
Moreover, several studies have reported a small or moderate increase in the risk of
myocardial infarction (MI) in persons with chronic exposure to opioids, due to
abuse/dependence or long-term opioid therapy for chronic pain (Carman et al., 2011;
Menendez et al., 2015; Sen et al., 2019). Conversely, it has been suggested that long-term
opiate exposure may mitigate the severity of coronary artery disease (Marmor et al.,
2004).
We set out to summarize systematically previous research on the association
between NOU and five CVD outcomes. The amount and strength of the evidence varied
across the outcomes. The most commonly studied outcomes were MI (10 reports) and IE
(7 reports). Across studies included in this review, was generally consistent evidence of a
positive association between community prevalence of injection drug use (with opioids
being the most commonly injected type of drug) and community prevalence of IE, and
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between nonacute opioid exposure (primarily for medical reasons) and MI incidence. The
other four outcomes were less commonly studied (three reports each for CAD,
arrhythmia and stroke; one for heart failure), and there was less consensus about their
relationship with opioid use. Many of the studies, for all outcomes, lacked detailed
information on the duration and dose of opioid exposure. Several studies have reported a
temporal association between the prevalence of IDU and the prevalence of IE in a
community, suggesting an increase in the prevalence of IE with increasing prevalence of
IDU. The sharing of needles and other materials promotes the spread of microbial
infections, with IE cases frequently resulting from Staphylococcal infection (Mylonakis
and Calderwood, 2001) . This, together with the fact that prescription opioids and heroin
are among the most commonly injected drugs (Cicero et al., 2017). Thus, increasing
exposure to opioids in a population can lead to greater prevalence of IE, by increasing the
prevalence of IDU within that population.
Coronary artery disease is the most common cause of MI, but is only directly
observable by invasive procedures, such as cardiac catheterization or coronary
angiogram, or at autopsy. This may explain why we identified 7 studies with MI as the
endpoint, but only 3 with CAD. Only 4 studies described detailed assessment of dose and
duration of opioid exposure, and all of these studies reported an association between
opioid use and MI (Carman et al., 2011; Jobski et al., 2017; Li et al., 2013; Roberto et al.,
2015).
Cardiac opioid receptors have been identified 48, but possible biological
pathways between nonacute opioid use and MI or CAD are still not well understood. Li et
al. (2013) speculated about possible relationships between opioids, hormones, including
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testosterone, and coronary atheroma, but their study did not explore these connections (Li
et al., 2013). Although some studies, such as that of Tanaka , attempt to address from a
molecular perspective the role of endogenous and exogenous opioids and cardiac opioid
receptors in limiting cardiac damage in acute MI patients (ischemic preconditioning,
opioid-induced cardio protection) (Tanaka et al., 2014), our findings suggest that longterm opioid exposure is associated with an increase in the incidence of acute MI.
In a systematic review of opioid use and arrhythmia Behzadi reported that, some
opioids, including methadone, tramadol and oxycodone, are associated with increased
risk of long QT syndrome, which in turn may lead to dangerous arrhythmias including
TdP (Behzadi et al., 2018). While arrhythmia was one of the cardiovascular conditions
included in our review, we found only 3 studies of the relationship between NOU and
cardiac arrhythmia that met our inclusion criteria. Our initial query returned a number of
articles on opioids and the QT interval, which, upon review, turned out to lack an
appropriate control group. As a result, those studies were excluded. Moreover, we
excluded studies of arrhythmias associated with acute opioid exposure as in, for example,
studies conducted among surgery patients or acute MI patients. Thus, although there is a
body of evidence linking use of certain opioids with the long QT syndrome, we found
little high-quality, epidemiological evidence examining directly the association of NOU
with cardiac arrhythmias per se. This appears to be a gap in need of future attention.
We found no studies that addressed the association of NUO with the risk of stroke
or heart failure in a general cohort that included a reliable assessment of dose and
duration of opioid use. The identified studies had one or more serious limitations,
including highly selective cohorts, a primary focus on short-term exposures, such as
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recent use, change of medication, discontinuation of medication, or inadequate
assessment of dose and duration. There remains a need for high-quality studies
examining the relationship between nonacute opioid use and stroke and CHF.
Much of the research on opioids and CVD has focused on acute exposures related
to surgical procedures or other treatment for acute medical conditions. Examples include
opioids used for anesthesia during surgery or for post-operative analgesia, and morphine
as part of treatment for acute MI. There has been relatively little high-quality research on
nonacute opioid exposure and its relationship with cardiovascular conditions. A
significant challenge for this type of research is the accurate assessment of the duration
and intensity of opioid exposure over an extended period of time. For example, estimated
that the period between the appearance of major risk factors for CAD – high serum
cholesterol and high systolic blood pressure – and their effects on morality may be 10
years or more (Rose, 2005). Exposure to prescription opioids is well-documented in
administrative claims databases, but members may be lost to follow-up if they change
insurance plans. Moreover, exposure to nonmedical use of opioids is practically
impossible to assess through secondary data sources.

2.6

Conclusion
In conclusion, this review of the literature on the association of nonacute opioid

use with the risk of cardiovascular events provides summative evidence that such
exposure poses a risk not only for cardiac disorders associated with infections due to
needle re-use, such as infective endocarditis, but may also predispose persons to chronic
cardiovascular disorders, including MI and arrhythmias. There is a dearth of high-quality
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evidence on the relationship between NOU and CVD. Many of the identified studies
lacked detailed information on the duration and intensity of opioid exposure and all were
retrospectively conducted. This is understandable, as the challenges to accurate
assessment of NOU are considerable. Innovative approaches to opioid exposure
assessment will be required.
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CHAPTER 3.
USING NATURAL LANGUAGE PROCESSING TO IDENTIFY
OPIOID USE DISORDER IN HOSPITAL AND EMERGENCY DEPARTMENT
ELECTRONIC HEALTH RECORD DATA
3.1

Abstract
As opioid prescriptions have risen, there has also been a rise in opioid use disorder

(OUD) and its related health issues and death, but epidemiologic surveillance is difficult.
Electronic health records (EHR) are one potential source of surveillance data, but the nature
of EHR data presents challenges [Howell, 2020]. The objective of this study was to
ascertain prevalence of OUD using two methods to identify OUD: applying natural
language processing (NLP) on unstructured clinical notes to identify OUD and using ICD10-CM diagnostic codes to identify OUD. Data were drawn from EHR information on
hospital and emergency department patient visits to a large regional academic medical
center from 2017 to 2019. EHR corresponding to 50 patient visits from 2017 and 30,124
patient visits from 2018 were used to develop and evaluate an NLP-based algorithm and
29,212 patients visits from 2019 to testing the algorithm. International Classification of
Disease, tenth Edition, Clinic Modification (ICD-10-CM) diagnostic codes were extracted
for each visit. We developed five unique dictionaries and six parsing rules for physician
mentions of opioid use disorder, and an NLP algorithm to identify these terms in
unstructured clinical text. To confirm the validity of the NLP results, physician on
manually reviewed randomly selected records. Prevalence of OUD was higher according
to NLP classification vs. ICD-10-CM codes. Based only on information contained in ICD10-CM codes, 1,811 patient visits were identified with an OUD diagnosis among the
29,212 visits (6.1%). In contrast, the NLP algorithm identified 1,902 (6.5%) visits with an
OUD classification. We estimated the sensitivity and specificity of EHR-based OUD

classification at 81.8%%, 97.5% respectively, relative to manual record review. NLP-based
algorithms can automate extraction and identify evidence of opioid use disorders from
unstructured electronic healthcare records. Combining with ICD-10-CM codes, More
OUD cases can be identified. It also will make the unstructured EHR notes useable for
researchers to do epidemiological study of OUD.

3.2

Background
Electronic health records are a rich source of data that can be leveraged to inform

strategies for measuring and addressing the ongoing opioid crisis in the United States
(Smart et al., 2020; Wang et al., 2018). Accurate and timely identification of patients with
opioid use disorder (OUD) is an important step in any such effort. International
Classification of Diseases (ICD) codes are commonly used for this purpose due to their
widespread use in medical record coding and their accessibility to researchers (Beam et al.,
2021; Mezzich, 2002). The limitations of ICD codes, including low sensitivity and
specificity for many conditions, have been well-documented (Hughes Garza et al., 2021;
Kurbasic et al., 2008; O'Malley et al., 2005; Quan et al., 2008), although there has been
little investigation of the extent to which this may pertain to the identification of OUD
cases(Palumbo et al., 2020).
In addition to ICD codes, EHR’s contain substantial information in the form of
unstructured, narrative text entered by providers, nurse, lab technician or any other member
of patient’s healthcare team as notes in the course of treatment (Spasic and Nenadic, 2020).
These clinical notes include information on patient symptoms, conditions, behaviors,
healthcare advice and plans, and more (Wang et al., 2018). Generally, information in
unstructured notes include demographics, medical encounters, developmental history,
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obstetric history, medications and medical allergies, family history, social history, habits,
immunization records (Gliklich et al., 2019).
Natural language processing (NLP) holds great promise as a tool for recovering
valuable information from unstructured textual data in many domains (Pendergrass and
Crawford, 2019). NLP is a branch of artificial intelligence that is concerned with computer
understanding of human languages (Baclic et al., 2020). Information extraction is a subtask
of NLP that is focused on the extraction of structured data from text (Ford et al., 2016;
Meystre et al., 2008). Typically, information extraction involves splitting text into basic
units called tokens, which are individual words, punctuation marks, etc. (Ford et al., 2016).
Rule-based approaches to information extraction attempt to identify matches of prespecified sequences of tokens (Nadkarni et al., 2011). Statistical approaches rely on
probabilistic models, or on supervised learning methods applied to very large corpuses of
text that have been labeled to indicate which instances do, and do not, contain the
information of interest (Carrell et al., 2015). In supervised learning approaches, systems
can be trained to recognize entities within text documents by seeing many correctlylabelled examples and “learning” features of the text that accurately predict the presence
of those entities (Spasic and Nenadic, 2020). Although powerful, a limitation of this
approach is the enormous effort required to create a sufficiently large, prelabeled corpus of
examples (Nadkarni et al., 2011; Velupillai et al., 2018).
Several recent reviews have demonstrated the potential for using NLP to extract
clinical information from EHR provider notes (Singleton et al., 2021). Wang et al. reported
on a sample of 135 peer-reviewed articles focused on identifying diseases or conditions
from clinical notes in EHR systems (“disease phenotyping”) (Wang et al., 2018). The most
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commonly studied diseases were cancer, venous thromboembolism, peripheral arterial
disease, and diabetes mellitus (Afzal et al., 2017; Datta et al., 2019; Woller et al., 2021;
Zheng et al., 2016). Many of the studies reported high sensitivity and specificity.
Sheikhalishahi et al. identified 106 peer-reviewed articles focused on the application of
NLP to free-text clinical notes related to chronic diseases, with the aim of transforming
clinical text into structured clinical data (Sheikhalishahi et al., 2019). The most commonly
studied chronic disease areas in this review were similar to those identified by Wang et al:
diseases of the circulatory system, neoplasms, and diabetes mellitus. It is not immediately
obvious why these particular conditions have been the most commonly studied.
Carrell and co-workers investigated the potential to apply NLP to EHR records to
increase the identification of problem use of prescription opioids (POU) among patients
undergoing chronic opioid therapy (Carrell et al., 2015). POU was defined as indications
of addiction, abuse, misuse or overuse, and is thus more broadly defined and less specific
than OUD. The study documented POU between 2006 and 2012 in a sample of 22,142
patients who received chronic opioid therapy, defined as at least a 70-day supply of
prescription opioid medications dispensed in a calendar quarter, within a large health plan
serving the state of Washington. They used a rule-based approach to identify “mentions”
of POU in clinical notes from patient’s EHR records, such as phrases of the form “opioid
addiction”, “dependence of methadone”, or “no evidence of drug abuse”. Candidate
mentions were then manually validated by trained reviewers. POU prevalence increased
under the NLP approach: POU prevalence was 10.1% based on ICD-9-CM codes alone,
and 13.4% including patients identified by NLP.
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Many patients with OUD who attend EDs and hospitals will not be undergoing
chronic opioid treatment (COT), and so the effectiveness of NLP approaches in broader
patient populations is unknown (Kaye et al., 2017). And, as noted, Carrell et al. used ICD9-CM-coded patient records (Carrell et al., 2015). In 2015, the United States transitioned
to ICD-10-CM for medical coding (Register, 2014). Thus, we aimed to conduct a study of
the application of NLP to OUD ascertainment in a general patient population where ICD10-CM codes are used. Drawing on inpatient and emergency department EHR records from
the University of Kentucky Albert B. Chandler Hospital (spanning 2017-2019), we
investigated the performance of NLP algorithms, relative to ICD-10-CM codes, in the
identifications of OUD cases.

3.3
3.3.1

Methods
Study Population
Data were drawn from all adult (age 18 years or older) inpatient and ED visits

occurring at the University of Kentucky HealthCare (UKHC) Albert B. Chandler Hospital
between January 1st, 2017 and December 31st, 2019. Due to high prevalence of opioid
use for the treatment of cancer-related pain (Wong and Cheung, 2020), we excluded visits
for patients with active cancer (ICD-10-CM code: C00-C27, C30-C42, C43-C59, C60C81, C7A.*, C7B.*, C81-C97, D37-D50) (Neoplasms, 2021). Additionally, we required
that patient visits had at least one of the following five types of notes, which we considered
most likely to include information pertaining to opioid use disorder: ED triage notes, ED
general notes, History and Physical notes, Addiction Medicine Consult notes, and
Discharge Summary notes. Table 3. 1 describes the application of inclusion and exclusion
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criteria. Care delivery was documented through Sunrise Clinical Manager (SCM) for
inpatient stays and emergency department (ED) visits. In addition to unstructured provider
notes, structured EHR data documenting delivered care includes information on patient
demographics, diagnoses, and problem lists. This study was approved by both the UK
Institutional Review Board (IRB# 20548) and the UKHC Data Management Committee.

3.3.2

ICD-10 definition of OUD
The ICD-10-CM definition for OUD included the codes for opioid abuse (F11.10,

F11.11, F11.12, F11.14, F11.18, F11.19), opioid dependence (F11.20, F11.21, F11.22,
F11.23, F11.24, F11.25, F11.28, F11.29), and unspecified opioid use (F11.90, F11.92,
F11.93, F11.94, F11.95, F11.98, F11.99). For each patient visit in the study sample, the
encounter was classified as positive for OUD if any of these diagnosis codes were present,
otherwise non-OUD.

3.3.3
3.3.3.1

NLP-based definition of OUD
Overview of algorithm development process
The NLP algorithm was developed in following phases—dictionary development

(Phase 1), parsing rule and algorithm development (Phase 2), and final classification (Phase
3). First, we used information from extant literature to create dictionaries of OUD-related
terms. The dictionaries were refined based on advice from an expert in medical toxicology
and emergency medicine (co-author PDA), and manual review of 25 randomly selected
patient visits occurring in 2017 with OUD identified by ICD-10-CM and 25 randomly
selected patient visits occurring in 2017 without OUD identification by ICD-10-CM. The
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developed dictionaries were used to create parsing rules to search evidence that the patient
visit did or did not indicate that a mention of OUD was appropriate.
We used data from patient visits occurring in 2018 to develop the algorithm. We
applied the initial version of the algorithm to the data to classify each encounter as OUD
or non-OUD. Next, to evaluate the performance of algorithm, we selected a 1% random
sample each from the visits classified as OUD and from the visits classified as non-OUD
for review. An expert clinician (co-author PDA) independently reviewed the EHR records
for these cases and classified them as OUD or non-OUD, without knowledge the
algorithmic classification. The conditions that were taken as evidence of OUD when
manually reviewing the cases were refined from a list reported in Carrell, and are listed in
Table 3.1 (Carrell et al., 2015). Based on findings from the manual review, we updated the
dictionaries and revised the protocol pipeline to optimize performance. The finalized
algorithm was then applied to the data set consisting of visits occurring in 2019.

Table 3. 1 Conditions indicating OUD
Condition indicating OUD
• Admits to opioid use
• Recent inpatient admission for detox
• Referral for opioid addiction treatment at the First Bridge Clinic
• Currently receiving methadone or suboxone treatment for opioid addiction
• Loss of control of opioid, craving
• Family member reported opioid addiction to clinician
• Current or recent opioid overdose
• Obtained opioids for multiple MDs surreptitiously
• Opioid taper/wean due to problems (not due to expected pain improvement)
• Unsuccessful taper attempt
• Physician or patient wants immediate taper
• Positive response to Narcan treatment
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3.3.3.2

Dictionaries
Five dictionaries were constructed (Table 3.2). We note that all dictionary terms

are lower case because we transformed the EHR text data into all lower case to facilitate
analysis. Based on published literature (Carrell 2015) and expert knowledge (author PDA),
we created dictionaries for opioid types (dictionary 1; e.g., “morphine”, “narcotic”,
“oxycodone”) and terms suggestive of use disorder (dictionary 2; e.g., “abuse”,
“dependence”, “use disorder”). Next, we queried our training database (2018 patient visits)
to refine these dictionaries. For example, we discovered spelling errors (e.g., “depandance”
for “dependence”), commonly used abbreviations (e.g., “Sub” for “Subutex”, “OD” for
“overdose”, “Vico” for “Vicodin”), and other types of nonstandard text. We created a third
dictionary consisting of terms (e.g., “denies”, “without”, “negative”) that are used in
clinical notes to negate a mention of OUD. The fourth dictionary was created to capture
specialized terms used at UKHC related to OUD, which were identified during review of
a random selected sample of 200 clinical notes from the training dataset visits that had an
OUD diagnostic code. Those terms were found primarily in the social history and related
to the negation of any drug use, e.g. “IVDA/intranasal: Denies”. The fifth dictionary
included the name of the UKHC opioid treatment clinic where patients may be referred to
following discharge (First Bridge Clinic)

36

Table 3. 2 Dictionaries of opioid, use disorder, and negation terms, and additional
specialized terms, which were combined via parsing rules to form OUD search phrases
Dictionary

Key words

1. Opioid term

fentanyl, heroin, hydromorphone, dilaudid, oxymorphone,
opanum, opana, methadone, oxycodone, oxycotin,
roxicodone, percocet, morphine, hydrocodone, vicodin,
vico, lortab, codeine, meperidine, demerol, tramadol,
ultram, meloxicam, kratom, carfentanil, buprenorphine,
meperidine, narcotic, dihydrocodeine, levorphanol,
naloxone, naltrexone, pentazocine, suboxone, subutex, sub,
tapentadol, vivitrol, opiate, opioid, opium

2. Use disorder terms

abuse, abuses, abused, abusive, abusing, addict, addicts,
addicting, addicted, addiction, dependence, dependant,
dependance, dependency, misuse, misuses, misused,
misusing, overdose, overdoses, overdoes, over dose, over
dosed, od, over use, over used, overuse, use disorder, usedisorder, inject, injected, injects, injection, injecting, ivda,
intravenous drug abuse, iv drug use, intravenous drug user,
iv drug user, ivdu, intravenous drug abuse, iv drug abuse,
iv drug abuse, iv drug abuser, withdrawal, withdraw,
withdrew, withdrawling

3. Negation terms

absence, absent, deny, denies, denied, denying, do not,
don’t, donnot, exclude, excluded, excludes, excluding,
lack, lacked, lacks, lacking, negative, negation, never, no,
no evidence, did not have, no history, no hx, no sign, no
signs, not observed, not present, without, without evidence,
suspect, suspected

4. Specialized terms

See Supplement Table 2 for specialized term lists

5. Specific clinic

first bridge clinic, the bridge
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3.3.3.3

Parsing rules
We developed six parsing rules representing combinations of dictionary terms

(Table 3.3). The clinical notes had a consistent structure. Each note consisted of some
number of sections that were separated into paragraphs, and each section started with a
keyword follow by a colon, and then finished with a period. For example, a discharge
summary note usually includes the following sections: reason for hospitalization,
Significant findings, Procedures and treatment, Patient's discharge condition, Patient and
family instructions, Attending physician's signature.
Notes were first parsed into sections. Sections were processed sequentially by first
parsing the section into sentences, and then parsing each sentence into individual tokens –
words, sub-words, abbreviations, punctuation marks, etc.
Parsing rule 1 consists of an opioid term (dictionary 1), followed by zero to three
other valid tokens, followed by a use disorder term (dictionary 2); for example, “opioid use
disorder”, “Oxycodone dependence”, or “heroin overdose” would return a classification of
positive for OUD. Parsing rule 2 consists of a problem use term (dictionary 2), followed
by zero to three other valid tokens, followed by an opioid term (dictionary 1). Examples of
parsed terms that would return a classification of positive for OUD are “dependent on
opioids”, “addicted to heroin”, and “abuse with opioids”. Parsing rule 3 is a negation rule
that consists of a negation term (dictionary 3), followed by zero to three other valid tokens,
followed an opioid term (dictionary 1), followed by a problem use term (dictionary 2).
Examples of parsed terms that would return a classification of negative for OUD are
“negative for opioid abuse” and “denied opioids addiction”. Parsing rule 4 is also a
negation rule that consists of an opioid term (dictionary 1), followed by a problem use term
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(dictionary 2), followed by zero to three other valid tokens, followed by a negation term
(dictionary 3). Examples of parsed terms that would return a classification of negative for
OUD include “opioid dependence is denied” and “opioid misuse is negative”. Parsing rule
5 is a searching rule included all the specialized terms in dictionary 4. Parsing rule 6 is
specific to UKHC and includes the first bridge clinic in dictionary 5.
Table 3. 3 Parsing rules defining the combinations of dictionary terms used in then
identification of OUD
Parsing rules

Rule contracture

Example

Rule 1

Opioid term + <= 3 tokens + use
disorder term

Opioid use disorder

Rule 2

Problem use term + <= 3 valid tokens
+ opioid terms

Addicted to suboxone

Rule 3

Negation term + <=3 valid tokens +
opioid terms + use disorder term

Denies opioid addiction

Rule 4

Opioid term + use disorder term +
<=3 valid tokens + negation term

Opioid dependence is denied

Rule 5

Specialized terms (use dictionary 4)

IVDA/intranasal: Denies

Rule 6

Specific clinic (use dictionary 5)

First Bridge Clinic

3.3.3.4

Opiate dependence

Implementation
The finalized algorithm was applied to the 2019 patient visit data. The NLP

algorithm was coded using the Python programming language and the Natural Language
Toolkit (NLTK and Spacy) modules (Bird, 2009; Honnibal, 2017); the logic and pipeline
is shown in Figure 3.1. Each EHR note is read by Python codes and parsed into sections.
The search rules were implemented as regular expression searches. The text in each section
was then converted to lowercase and scanned for terms in dictionaries 1 and 5. If a match
was found, the section was further separated into sentences. Each sentence was then
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scanned for mentions of OUD matching one of the negation rules (parsing rules 3, 4 and
5). If there was a match, a negative OUD mention record was created, which included the
matching text, the parsing rule to which it matched, and the document name. If no matching
terms were found, the next section was processed. Otherwise, the algorithm continued
scanning the same sentence for matches to parsing rules 1, 2 and 6 (positive OUD
mentions). If a match was found, an OUD mention record was created and continue to
search whole document. One or multiple OUD mentions can be identified from one
document. If no match was found, the next sentence was processed. In this way, all
mentions of OUD appearing in a clinical note associated with a particular visit are extracted
and classified as either positive or negative mentions of OUD.

3.3.3.5

Classification.
To classify each patient visit as “OUD” or “non-OUD”, we applied the following

logic: if all mentions of OUD for a visit were positive, we classified it as OUD. If a visit
had no mentions of OUD, or if all identified OUD mentions were negative, the visit was
classified as “non-OUD.” A small proportion of visits had both positive and negative
mentions of OUD. We manually reviewed these cases and classified them as OUD or nonOUD.
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Figure 3. 1 Parsing and classification process for individual mentions of opioid use
disorder in electronic health record unstructured clinical notes
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3.3.3.6

Statistical methods
Sensitivity and specificity of the NLP algorithm were computed with reference to

300 manually-reviewed cases as the ground truth diagnosis. OUD cases were compared
between the classifications by the NLP algorithm and by ICD-10 codes. Demographic
characteristics of patients classified as positive for OUD by ICD-10 only, NLP only, and
both ICD-10 and NLP were compared using means (Smart et al.) and proportions.

All

statistical analyses were carried out using SAS 9.4® M6 (SAS Inc, Cary, NC).

3.4

Results
We identified 29,212 hospital inpatient and Emergency Department visits occurring

in 2019 (1,440 ED [4.9%] and 28,079 hospital [95.1%]) meeting inclusion criteria. Those
visits generated 116,974 unstructured clinical notes, an average of 3.96 notes per patient
visit. These notes comprised 59,780 discharge summaries (51.1% of all notes) (One visit
may include several discharge summaries due to behavior discharge note was categorized
as discharge summary notes), 22,080 History and Physical notes (18.9%), 18,679 ED
General notes (16.0%), 14,927 ED Triage Notes (12.8%), and 1,508 Addiction Medicine
Consult notes (1.3%).
About 67.0% of the study patients were between 35 and 74 years old, 20.4% were
between 18 to 34 years old, and 12.9% were 75 years or older at the time of visit. The
majority of patients’ visits were among male patients (52.0%) and with patient race
reported as White for 88.5% of the visits. Ten percent of patient visits were among Black
patients (9.9%), and patients with reported other or unknown races accounted for 1.6%.
Similarly. Hispanic, the majority of patients were reported as non-Hispanic ethnicity
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(86.4%), and Hispanic ethnicity was reported for 2.8% patients, with the remainder having
no ethnicity information reported. visits.

3.4.1

OUD case ascertainment by ICD-10-CM
We identified 1,811 visits having any ICD-10-CM code for OUD. Of these, 57

(3.1%) were ED visits and 1,754 (96.9%) were inpatient hospital stays. The numbers of
visits having each ICD-10-CM code for OUD are shown in Supplement table 3.1. Based
on ICD-10-CM coding, opioid dependence accounted for 48.9% of OUD diagnoses, opioid
abuse for 42%, and unspecified opioid use for 9.1%.

3.4.2

OUD case ascertainment by NLP
The NLP algorithm identified 1,902 patient visits as having evidence of OUD in

the unstructured clinical notes. Of these, 1,844 (97.0%) were identified from hospital visit
data and 58 (3.0%) from ED visits. The NLP algorithm identified 24,822 total mentions
of OUD across the 29,212 visits and the five selected note types. ED General Notes and
History and Physical Notes contained a majority of OUD mentions, and these tended to be
negative (for example, denial of opioid misuse). Nearly 74% of the positive mentions of
OUD were identified in Discharge Summary Notes or Addiction Medicine Consult Notes,
with another 18.3% identified in History and Physical Notes. Most of the negative mentions
of OUD (94%) came from ED General Notes or History and Physical Notes. (Table 3.4).

Table 3. 4 Distribution of OUD mentions by note type
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Note Group
ED General Notes
History and Physical notes
Discharge Summary Notes
Addiction Medicine
Consult Notes
ED Triage Notes
Total

Mentions of OUD
(n=22,715)
10,676 (47.0%)
6,949 (30.5%)
3,948 (17.3%)
1,972 (8.7%)
75 (0.3%)
22,715 (100%)

446 (7.2%)
1,134 (18.3%)
2,710 (43.8%)
1,841 (29.8%)

Negative
mentions of
OUD2
(n=16,529)
10,230 (61.9%)
5,360 (32.4%)
788 (4.8%)
131 (0.8%)

55 (0.9%)
6,186 (100%)

20 (0.1%)
16,529 (100%)

Positive mentions
of OUD1 (n=6,186)

1 A positive mention of OUD is one which indicates the presence of OUD for the present
visit
2 A negative mention of OUD is one which indicates the absence of OUD (e.g. “patient
denies opioid abuse,” refers to a historical condition (e.g. “history of opioid abuse”), etc.

3.4.3

Comparison of results
OUD cases identified by ICD-10-CM and NLP is summarized in Figure 3.2. The

absolute number of visits with evidence of OUD identified by each method was similar,
with NLP identifying 91 more cases. While there was substantial overlap in the identified
cases (1,381 [59.2%]), overall 2,332 unique visits were identified. Of the total unique visits,
430 (18.4%) were identified only by ICD-10-CM codes, and 521 (22.3%) were identified
only by NLP.
The prevalence of visits with evidence of an OUD diagnosis in this sample,
ascertained using only ICD-10-CM codes, was 1,811/29,212 (6.1%). Including the
additional 521 visits identified only by NLP, the estimated prevalence of OUD is
2,332/29,212 (7.9%), an increase of 29.5%.
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Demographics characteristics of patient visits with a mention of OUD are presented
in Table 3.5. Compared to ICD codes alone, NLP codes alone identified a greater
proportion of males (54.7% vs. 49.1%), patients age 55 or older (29% vs. 17.7%), Black
patients (10% vs. 5.1%) and Hispanic patients (1.3% vs. 0.5%), and married patients
(23.2% vs. 17.2%).
ICD10: 1,811

NLP:
1,902

521

1,381

430

Figure 3. 2 Numbers of OUD visits identified by ICD-10-CM codes only, NLP algorithm
only, and both ICD-10-CM codes and NLP algorithm; and total number of OUD visits
identified by each method
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Table 3. 5 Cases characteristics by ascertainment method
Characteristics
Gender
Male
Female
Age
18-34
35-54
55-74
75+
Race
African American
European American
Other
Ethnicity
Hispanic
Non-Hispanic
Other

3.5

OUD-ICD
only (n=430)

OUD-NLP only
(n=521)

Common
(n=1,381)

211 (49.1%)
219 (50.9%)

285 (54.7%)
236 (45.3%)

672 (48.7%)
722 (52.3%)

127 (29.5%)
227 (52.8%)
71 (16.5%)
5 (1.2%)

118 (22.6%)
252 (48.4%)
135 (25.9%)
16 (3.1%)

507 (36.7%)
692 (50.1%)
169 (12.2%)
13 (0.9 %)

22 (5.1%)
405 (94.2%)
3 (0.7%)

52 (10.0%)
461 (88.5%)
8 (1.5 %)

54 (3.9%)
1318 (95.4%)
9 (0.7%)

2 (0.5%)
379 (88.1%)
49 (11.4%)

7 (1.3%)
448 (86.0%)
66 (12.7%)

6 (0.4%)
1211 (87.7%)
164 (11.9%)

Discussion
We measured the prevalence of opioid use disorder in UKHC hospital and

emergency department patients using ICD-10-CM codes and an NLP rule-based algorithm.
Our study identified 1,902 OUD (6.4%) visits out of 29,212 total visits by NLP algorithm,
while a search of ICD-10-CM codes identified 1,811(6.1%) OUD cases from the same
population. Combining ICD- and NLP-identified OUD visits gives 2,332 (7.9%) OUD
cases in our sample.
Similar methods have been applied to a wide range of disease conditions (Afzal et
al., 2016; Datta et al., 2019; Woller et al., 2021; Zheng et al., 2016). Here we mention only
a few examples. Tian et al (2015) reported 0.94 sensitivity (Tian et al., 2017), 0.96
specificity and 0.73 PPV for identifying DVT in narrative radiology reports by NLP. Afzal
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et al (2016) reported sensitivity 0.96, specificity 0.98 and PPV 0.92 for identifying PAD in
clinical EHR notes using HER (Afzal et al., 2016). Wright et al (2013) reported areas
under the curve (AUC) of 0.956 and 0.947 at two separate hospitals for identifying diabetes
in EHR progress notes (Wright et al., 2013).
Application to OUD has been less common. Carrell et al. (2015) used a rule-based
NLP approach to identify 1,875 (8.5%) patients with problem prescription opioid use
(POU) in a sample of 21,795 patients who were receiving chronic opioid therapy (Carrell
et al., 2015). An ICD-9-CM code search identified 2,240 (10.1%) patients with POU from
the same sample. Our study found a similar result for OUD in a broader population of
patients that was not restricted to those receiving chronic opioid therapy.
The discrepancy between ICD- and NLP-identified OUD in our study has several
possible explanations. First, we did not search all clinical notes. Instead, we selected only
the 5 types of notes that we believed were most likely to contain mentions of OUD. This
could account for some cases in which the ICD code search identified a case of OUD but
the NLP algorithm did not. Second, certain terms used to refer to OUD in text notes are
ambiguous. For example, upon manual review, we identified cases in which the ICD code
search identified a case of OUD and the NLP algorithm failed to identify a mention of
OUD. However, the note text contained a reference to “polysubstance abuse.” Third, Other
reason may cause by ICD10 missed coded by coders, some cases specified that the patient
“denied drug use” and no other opioid use information was mentioned in any notes, but
there was an ICD10 code for this case.
There were several significant differences in the demographic characteristics of
patients with OUD identified by NLP and ICD. The group of patients identified only by
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NLP included slightly higher percentages of males, older patients, black patients and
Hispanic patients. It is not immediately clear why these differences should exist.

3.6

Limitations
In this study, we used a rule-based NLP algorithm to analyze electronic notes from

patient visits to identify OUD cases, and we compared the results to cases identified using
a search of ICD-10-CM codes. Our sample was limited to hospital and emergency
department visits in a single healthcare setting. The findings cannot be generalized to all
healthcare settings.

We limited the text mining search to five types of notes that were

considered most likely to include mentions of OUD. In particular we did not include
psychiatry notes that include behavioral and mental health information. In our rule-based
algorithm, the development of keyword dictionaries and parsing rules relied on literature
reviews and expert opinion. Although we included over 1,000 entries that healthcare
workers might use to describe OUD in text notes, it is still possible that terms were missed
by our dictionaries and parsing rules. In particular, OUD mentions that contain
abbreviations or spelling errors may type error result in false negatives. Finally, negation
rules are imperfect, and may result in misclassification of cases. For example, one of our
negation rules allowed 3 or fewer tokens between the negation term and the opioid use
term. This rule would fail to correctly negate the following, mention of OUD: “Patient
denies fevers or chills, vomiting or diarrhea, and IV drug abuse”.
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3.7

Conclusion
The findings in this study concluded that it is feasible to identify patients with OUD

by rule-based NLP algorithm from unstructured clinical notes. It suggested that rule-based
NLP algorithm applied to identify potential OUD cases have the potential to improve
surveillance of opioid use disorder compare to the traditional methods that only rely on
ICD-10-CM codes.
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CHAPTER 4. EFFECT OF EXPOSURE MISCLASSIFICATION ON THE
ASSOCIATION BETWEEN OPIOID USE DISORDER AND
CARDIOVASCULAR DISEASE RISK
4.1

Abstract
In recent years, concerns have emerged about possible cardiovascular effects of

opioid use. One common approach to studying this relationship involves administrative
hospital records, using International Classification of Diseases (ICD) codes for opioid use
disorder (OUD) as a proxy for opioid exposure. This type of study is common due to the
convenience, low cost and ready availability of administrative hospital data. However,
reliance on ICD codes only can lead to potential misclassification of OUD status and bias
effect estimates examining the association of OUD with the risk of cardiovascular disease.
In a previous study of 29,519 inpatient hospital and emergency department visits, we
identified patient visits where the patient was classified as having OUD using ICD-10-CM
codes (F11.1*, F11.2*, F11.9*) and separately using a rule-based natural language
processing (NLP) algorithm from unstructured clinical notes. Using this sample, we
conducted a cross-sectional study to estimate the association between OUD and six
cardiovascular diseases (CVD) and conditions. Prevalence of OUD was ascertained from
ICD codes alone or ICD codes plus NLP algorithm applied to clinical notes. Multivariable
Poisson regression models, with a robust variance estimator, were used to estimate
prevalence rate ratios to quantify the association between OUD and CVD prevalence. Our
sample included 22,501 adult inpatients. Prevalence of OUD was identified from ICD-10CM codes for 1,478 patients. Another 391 patients could only be identified by an NLP
algorithm applied to unstructured clinical notes. Changes in prevalence rate ratio estimates,
when patients with OUD that was only identifiable by NLP analysis of clinical notes were
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reclassified from non-OUD to OUD, were modest. All of the changes were less than 10%
different from the estimates that were based on OUD assessment using ICD-10-CM codes
alone. We observed modest effects of misclassification of OUD status on estimates of the
association between OUD and CVD. However, weak but statistically significant
associations could result from misclassification of OUD status based on ICD-10-CM
codes, when in fact no association exists. Estimates from administrative data should be
interpreted with caution.

4.2

Background
Exposure to opioid drugs among United States (U.S.) residents has increased

exponentially over the past 30 years (Hedegaard et al., 2018). This includes the use of
prescription opioids for medical purposes as directed by a physician – such as for treatment
of cancer-related or noncancer chronic pain – as well as non-medically indicated use of
both prescription and illicit opioids (Cochran et al., 2015; Kaye et al., 2017; Khodneva et
al., 2016). Between 1997 and 2007, opioid prescribing in the U.S. increased from 100 to
nearly 700 morphine milligram equivalents per capita (Paulozzi et al., 2011). This increase
in opioid availability has been accompanied by steep increases in fatal and nonfatal
overdoses as well as increases in the prevalence of opioid use disorder (OUD) (Haight et
al., 2018; Martins et al., 2017).
In recent years, concerns have emerged about possible cardiovascular
effects of opioid use (Khodneva et al., 2016). The risk of infective endocarditis associated
with injection drug (including opioid) use has been well-documented (Mihm et al., 2020;
Sinner et al., 2021). In a review of the relationship between opioid use and cardiac
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arrhythmia, Behdazi et al (2018) reported that methadone posed a high risk of QT interval
prolongation and arrhythmogenicity, even at low doses (Behzadi et al., 2018).
Previously we published a review of research on nonacute opioid use – which we
defined to include chronic opioid therapy and opioid use disorder (OUD) – and CVD
prevalence (Singleton et al., 2021). We summarized the literature on the association
between NOU and 5 classes of cardiovascular disease, including infective endocarditis
(IE), coronary heart disease, acute myocardial infarction (MI), congestive heart failure,
cardiac arrythmia, and stroke. There was generally consistent evidence of a positive
association with the risk of IE and MI. There was less consensus about the relationship
between NOU and the risk of heart failure, cardiac arrhythmia, and stroke.
Methodologically, several of extant studies relied on administrative hospital
records (Dakour-Aridi et al., 2019; Gupta et al., 2016; Menendez et al., 2015), using a
diagnosis of opioid use disorder (OUD) as a proxy for opioid exposure. Both OUD and
cardiovascular conditions can be identified from electronic health records using
International Classification of Diseases (ICD) codes. The limitations of ICD codes,
including low sensitivity and specificity, have been well-documented for many conditions
(Hughes Garza et al., 2021; Kurbasic et al., 2008; O'Malley et al., 2005; Quan et al., 2008),
although there has been little investigation of the extent to which this may be true for OUD.
If ICD codes have low sensitivity to identify OUD when it is present, then many patients
with OUD could be misclassified as not having OUD. This could result in biased estimates
of the association between OUD and any other conditions of interest, including CVD.
The objective of this study was to assess the degree to which incomplete
identification of OUD based on ICD codes could bias the estimated association between
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OUD prevalence and the risk of CVD. Study data were drawn from a unique data set
consisting of hospital and emergency encounters from the electronic health record (EHR)
of a single academic medical center. OUD was classified into two sets, one was only by
ICD-10-CM diagnostic codes, and the other was by either ICD-10-CM codes or by NLP
algorithm on unstructured clinical notes. Using this data set, we estimated univariable
(“crude”) and multivariable (“adjusted”) associations between OUD and 6 types of CVD,
with these two sets of OUD and discussed the effect of misclassification of OUD on the
association of OUD and CVD.

4.3
4.3.1

Methods
Data Source and study sample
University of Kentucky HealthCare (UKHC) documents were delivered through

Sunrise Clinical Manager (SCM) EHR for inpatient visits before June 2021. Structured
data documenting delivered care include, but are not limited to, information on patient
enrollment, clinical encounters, demographic characteristics, diagnoses, procedures,
problems, medications, and laboratory orders and results. Clinical notes can be obtained
from EHR as unstructured data elements. This study was approved by both the UK
Institutional Review Board (IRB #20548) and the UKHC Data Management Committee.
The sample consisted of hospital inpatient and emergency department visits to
UKHC for adults age 18 years of age or older, occurring between January 1, 2019 and
December 31, 2019. We excluded patients with active cancer due to their high level of
opioid use, which does not necessarily reflect OUD (Alzeer et al., 2018). We summarized
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the visit-oriented sample (potentially multiple visit records per patient) into a patientoriented sample (one record per patient, N=22,501) by scanning over all visits for the
exposure (OUD) and outcome (CVD) of interest in 2019.

4.3.2

Exposure
The exposure was OUD, ascertained by two methods: OUD identified by ICD

codes alone, and OUD identified by either ICD codes or NLP applied to clinical notes. The
ICD-10-CM codes used to identify OUD were F11.1* for opioid abuse, F11.2* for opioid
dependence and F11.9 for unspecified opioid use.
From our previous study, we identified 1,811 patients visits with an ICD-10-CM
code for OUD, and 1,902 patients visits with OUD mentioned in clinical notes. Of the
1,902 visits with OUD identified by NLP, 591 (21%) were not identifiable by ICD-10-CM
codes (i.e., there was no ICD-10-CM code documenting OUD). In this study, we looked at
the OUD status in patient level instead of patient visit level. There are four conditions for
which we had to convert observations from the patient visit level to the patient level (Table
4.1)

For example, if a patient visit was classified as having OUD only by ICD-10-CM

code, then this patient was classified as OUD by ICD; if a patient visit was classified as
OUD only by NLP, then this patient was classified as OUD by NLP; if a patient visit was
classified as OUD by both ICD and NLP, then this patient was classified as common; if a
patient had multiple visits, and one visit was classified as OUD by ICD and the others
classified as OUD by NLP, then this patient was classified as common. Proportions of
OUD patients classified according to information obtained from ICD-10-CM or NLP are
shown in Figure 4.1.
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Table 4. 1 Convert patient visit level to patient level
Patient visit ID OUD status for visit
Patient ID
000000001-0001
OUD_NLP 000000001
000000002-0001
OUD_NLP 000000002
000000003-0001
Common 000000003
000000004-0001
OUD_NLP 000000004
000000004-0002
OUD_ICD 000000004

OUD status for patient
OUD_NLP
OUD_NLP
Common
Common
Common

In this sample of patients (N=22,501), we identified 1,478 patients with an ICD10-CM code for OUD, and 1,467 patients with OUD mentioned in clinical notes. Of the
1,467 visits with OUD identified by NLP, 391 (21%) were not identifiable by ICD-10-CM
codes (i.e., there was no ICD-10-CM code documenting OUD). Numbers of OUD patients
classified according to information from ICD-10-CM or NLP are shown in Figure 4.1.

NLP: 1,467

391

ICD10: 1,478

1,076

402

Figure 4. 1 Numbers of OUD Patients identified by ICD-10-CM codes only, NLP
algorithm only, and both ICD-10-CM codes and NLP algorithm; and total number of
OUD patients identified by each method
4.3.3

Outcome: CVD conditions
Prevalence of cardiovascular conditions was assessed by scanning all diagnosis

codes associated with the hospital visits occurring in 2019. ICD-10-CM codes for
cardiovascular conditions are listed in Supplemental Table 4.1. The types of CVD
conditions identified included cardiac arrhythmia, heart failure, acute myocardial
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infarction (MI), stroke, ischemic heart disease, and infective endocarditis. These conditions
were selected due to their high prevalence and public health impact. There is research
suggesting that ICD codes for MI, arrhythmias and stroke have good sensitivity and
specificity (Birman-Deych et al., 2005 ; Frolova et al., 2015; Jensen et al., 2012; Kivimaki
et al., 2017; Metcalfe et al., 2013). Significant misclassification of heart failure is to be
expected when using ICD codes (Rosamond et al., 2012). In this study, we did not take
potential misclassification of CVD outcomes into account.

4.3.4

Covariates
Possible confounders of the association between OUD and CVD, assuming a causal

relationship exists, were identified based on the review of extant literature and construction
of a directed acyclic graph (DAG; Figure 4.2). Based on the literature review and the
minimal sufficient adjustment set identified by the DAG (Hernan and Robins, 2020), we
included the following demographic variables: patient age at first visit in 2019, gender,
race/ethnicity; clinical comorbidity variables: hypertension, diabetes, and the total number
of inpatient visits in 2019 as a proxy for healthcare utilization. Prevalence of hypertension
and diabetes at the time of hospitalization was identified from ICD-10-CM Codes: E11.9
for diabetes and I10 for Hypertension.
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Figure 4. 2 Directed acyclic graph (DAG) of the association of opioid use disorder
(OUD) with the prevalence of cardiovascular disease (CVD)
Note: Red lines indicate non-causal pathways

4.3.5

Study design and Statistical Analysis
Characteristics of patients, stratified by the method of OUD ascertainment (ICD or

NLP), were summarized using means and frequencies.
We conducted two versions of a cross-sectional study to estimate the association
between OUD and the prevalence of CVD conditions. Poisson regression models, with a
robust variance estimator, were used to estimate prevalence rate ratios (Barros and
Hirakata, 2003) quantifying the association between OUD and CVD prevalence. In one
set of models, OUD was identified only using ICD-10-CM codes (all patient visits without
an ICD-10-CM code for OUD were coded as non-OUD). In the second set of models, OUD
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was identified from ICD-10-CM codes and through NLP of clinical notes (here, all patient
visits without any ICD code for OUD or any evidence of OUD from the clinical notes were
coded as non-OUD). Estimates from the two sets of models were compared to assess the
potential bias due to misclassification resulting from under-ascertainment of OUD from
ICD codes. Multivariable models included the covariates listed above and the model was
specified as:
Model 1: Log(Pr*CVD) = β0 + β1*OUD_ICD + β2*Age_group + β3*Gender +
β4*Race + β5*Ethnicity + β6*Diabetes + β7*Hypertension + β8*Visit_Count
Model 2: Log(Pr*CVD) = β0 + β1*OUD_ICD/NLP + β2*Age_group + β3*Gender
+ β4*Race + β5*Ethnicity + β6*Diabetes + β7*Hypertension + β8*Visit_Count
Note: Pr* is the probability of a patient having CVD, conditional on the values of
the independent variables.
The statistical significance level for this study was fixed at 0.05. All analyses were
conducted using SAS version 9.4 TS (SAS Institute, Cary, NC).

4.4

Results
Our sample included 22,501 adult patients. A diagnosis of OUD, based on ICD-10-

CM codes was available for 1,478 patients. Another 391 patients could only be identified
as having OUD from an NLP algorithm applied to unstructured clinical notes. Table 4.2
summarized different types of CVD identified in different OUD or non-OUD groups. Table
4.3 summarizes the characteristics of these patients. As compared to patients with OUD
who could be identified by ICD codes, patients with OUD that could only be identified by
NLP they were older (46.3 years vs. 40.9 years), higher percentage male (55% vs. 47.8%)
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and African American (9.2% to 4.9%), and had higher prevalence of diabetes (12.3% vs.
8.2%) and hypertension (40.9% vs. 32.5%).

Table 4. 2 CVD identification in different OUD groups
OUD by ICD OUD by NLP only
(n=1,478)
(n=391)
Overall CVD
667 (6.2)
184 (1.7)
Cardiac arrhythmia
Acute myocardial
infarction
Stroke
Heart failure
Ischemic heart disease
Infective endocarditis

Non-OUD
(n=20,632)
9909 (92.1)

546 (7.4)
50 (4.3)

132(1.8)
16 (1.4)

6734 (90.9)
1095 (94.3)

Total
(n=22,501)
10,760
(100%)
7,412 (100%)
1,161(100%)

113 (4.1)
138 (3.0)
162 (4.9)
13 (65.0)

27 (1.0)
62 (1.3)
61 (1.9)
1 (5.0)

2598 (94.9)
4433 (95.7)
3071 (93.2)
6 (30.0)

2,738 (100%)
4,633 (100%)
3,294 (100%)
20 (100%)

Table 4. 3 Characteristics of all patients and patients by OUD status as ascertained by
ICD-10-CM or NLP

Age, mean
Male, Sex (%)
Race, (%)
European American
African American
Ethnicity, (%)
Non-Hispanic
Others
Diabetes
Hypertension
Visit Counts

All Patients
(n=22,501)
53.2 (18.8)
10677 (47.5%)

All OUD*
(n=1,869)
42.1 (13.1)
922 (49.3%)

OUD_ICD
(n=1,478)
40.9 (12.3)
707 (47.8%)

OUD_NLP only
(n=391)
46.3 (14.8)
215 (55.0%)

20136 (89.5%)
2365 (10.5%)

1760 (94.2%)
109 (5.8%)

1405 (95.1%)
73 (4.9%)

355 (89.4%)
36 (9.2%)

18830 (83.7%)
3671 (16.31)
3570 (15.9%)
9608 (42.7%)
1.3 (0.9)

1593 (85.2%)
276 (14.8%)
169 (9.0%)
641 (34.3%)
1.6 (1.6)

1265 (85.6%)
213 (14.4%)
121 (8.2%)
481 (32.5%)
1.6 (1.6)

328 (83.9%)
63 (16.1%)
48 (12.3%)
160 (40.9%)
1.7 (1.7%)
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Note: All OUD is ascertained either by ICD-10-CM or NLP
Figure 4.3 presents the differences in the proportion of patients with OUD
discoverable only by NLP analysis of clinical notes, for patients with and without each type
of CVD. We compared the prevalence of CVD or non-CVD that was identified from
patients with OUD identified by NLP. The differences were greatest for stroke, ischemic
heart disease and acute MI. In other words, there is some amount of differential
misclassification of OUD status for these three types of CVD.

Figure 4. 3 Proportion of CVD conditions and non-CVD conditions where OUD was
ascertained only by NLP

Table 4.4 presents crude prevalence rate ratio estimates for CVD when OUD was
assessed by ICD-10-CM codes alone or by ICD-10-CM codes combined with NLP. The
change in the prevalence ratio point estimates when assessment of OUD was expanded to
include cases identified by NLP was generally less than 5%. The point estimate for
ischemic heart disease increased by 13.6% and the point estimate for heart failure increased
by 8%.
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Table 4. 4 Crude prevalence rate ratios for cardiovascular disease by opioid use disorder
(OUD) ascertainment method

Dependent variable
Any cardiovascular disease
Cardiac Arrhythmia
Acute myocardial infarction
Stroke
Heart failure
Ischemic heart disease
Infectious endocarditis

OUD by ICD-10-CM OUD by ICD-10-CM + NLP
0.94 (0.89-1.00)
0.95 (0.90-1.00)
1.13 (1.06-1.21)
1.11 (1.04-1.18)
0.64 (0.48-0.85)
0.67 (0.52-0.85)
0.61 (0.51-0.73)
0.59 (0.51-0.70)
0.74 (0.63-0.85)
0.80 (0.71-0.91)
0.44 (0.37-0.51)
0.50 (0.44-0.57)
26.4 (10.5-66.1)
25.7 (9.9-66.9)

Table 4.5 presents the adjusted prevalence rate ratio estimates when age, gender,
race, ethnicity, diabetes, hypertension, and number of inpatient visits in 2019 are taken into
account. Compared to the crude estimates, the adjusted estimates for all types of CVD
changed. For any cardiovascular disease and heart failure, the changes accrued in both
direction and magnitude. This was due primarily to the imbalances in patient characteristics
for patients with or without OUD. As table 4.3 shows, patients with OUD were on average
much younger than xxx, and age is a strong risk factor for CVD. However, the differences
in xxx by OUD ascertainment method between the sets of adjusted estimates were fairly
small. The largest difference was for stroke: a decrease of 8.3% (from 0.96 to 0.88). The
estimate for ischemic heart disease increased by 6.3% (0.80 to 0.85). The adjusted
estimates for the other CVD types changed by less than 5% given ascertainment by NLP.
This suggests that the effect of misclassification of OUD based on using ICD-10-CM codes
alone was small.
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Table 4. 5 Adjusted prevalence rate ratios for cardiovascular disease when OUD is
assessed by ICD-10-CM codes alone and by ICD-10-CM codes and NLP together
OUD by ICD-10-CM OUD by ICD-10-CM + NLP
Dependent variable
Any cardiovascular disease
1.26 (1.19-1.34)
1.22 (1.16-1.29)
Cardiac Arrhythmia
1.41 (1.31-1.52)
1.34 (1.25-1.43)
Acute myocardial infarction
0.94 (0.7-1.26)
0.92 (0.71-1.18)
Stroke
0.96 (0.8-1.15)
0.88 (0.75-1.04)
Heart failure
1.15 (0.98-1.35)
1.20 (1.05-1.36)
Ischemic heart disease
0.80 (0.69-0.94)
0.85 (0.74-0.96)
Infectious endocarditis
18.7 (6.95-50.3)
18.78 (6.8-51.82)

4.5

Discussion
We investigated the degree to which under-ascertainment of OUD by ICD-10-CM

codes could bias the estimated association between OUD and six types of CVD, in a sample
of patients identified from the EHR system of an academic medical center. Changes in
prevalence ratio estimates, when patients with OUD that was only identifiable by NLP
analysis of clinical notes were reclassified from non-OUD to OUD, were modest. All of
the changes were less than 10% different from the estimates that were based on OUD
assessment using ICD-10-CM codes alone.
When misclassification bias is nondifferential, there is a tendency for effect
estimates to be biased towards the null value (Whitcomb and Naimi, 2020). When
differential, the result is less predictable (Li and VanderWeele, 2020; Sorahan and
Gilthorpe, 1994). In this study, misclassification of OUD based on ICD-10-CM codes was
nondifferential for stroke, acute MI, IHD and IEF or IE, although IE was uncommon in our
sample, therefore, the robustness of this estimate is questionable. The impact of OUD
ascertainment method on the estimated prevalence ratio for IE was minimal.
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The adjusted prevalence rate ratios for heart failure illustrate the potential for more
complete ascertainment of OUD to affect conclusions. In Table 4 we reported that when
OUD cases identified only by NLP were reclassified, the point estimate for heart failure
increased from 1.15 to 1.20, and the limits of the 95% confidence interval increased from
(0.98-1.35) to (1.05, 1.36). The confidence intervals also narrowed slightly in Model 2 for
all CVD outcomes due the increasing sample size after the OUD cases identified by NLP
were included.
In our multivariable models, we adjusted for several potential confounders of the
association of OUD with the risk of CVD, that were identified based on published data.
These variables were incorporated into a directed acyclic graph (DAG) to identify a
minimally sufficient adjustment set. Ideally, in addition to the specified covariates, the
DAG should have included smoking and alcohol use as those behaviors are known to
associated with the prevalence of OUD and CVD. However, information on smoking and
alcohol is not reliably captured in EHR data, so we did not include it.
Logistic regression is often used to estimate the odds ratio for a binary outcome in
cross-sectional studies. For common outcomes such as CVD, the odds ratio can be
misleading as a measure of the prevalence ratio. Poisson regression provides a direct
estimate of the prevalence rate ratio. Applying Poisson regression to a binomial outcome
will tend to overestimate standard errors for parameter estimates. However, this can be
addressed using robust variance estimation, which is the approach we took in this study
(Barros et al. 2003).
NLP applied to clinical notes can be used to assess the extent and impact of
misclassification bias in research using ICD-coded medical record data. Unstructured
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clinical notes can be transformed into structured information for analysis. However, these
methods do require a considerable investment of resources, including skilled analysts and
medical experts who can manually review cases to assess algorithm performance.

4.6

Conclusion
The effects of misclassification of OUD status on estimates of the association

between OUD and CVD prevalence were very modest in this study. Weak, but statistically
significant, associations could result from misclassification of OUD status based on ICD10-CM codes, when in fact no association exists. Such estimates should be interpreted with
caution.
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CHAPTER 5.
5.1

CONCLUSION

Summary
As the prevalence of long-term exposure to opioid drugs has increased considerably

since 1990’s, concerns have arisen about the potential cardiovascular effects of opioid use.
This is a challenging topic to study for several reasons, the major one being the difficulty
of accurately assessing an individual’s exposure to opioid drugs. For example, in healthcare
data, patient symptoms, conditions, behaviors and compliance with health care team
advices may be documented in unstructured text notes and/or problem lists but not
diagnosis codes. Additionally, some caregivers may be reluctant to assign diagnosis codes
for opioid use disorder because of associated stigma and the relative ease with which this
information is detectable through automated surveillance. The primary aims of this
dissertation research were to demonstrate the utility of natural language processing (NLP)
to identify cases of opioid use disorder (OUD) in electronic health records (EHR) that
cannot be identified by ICD-10-CM codes; and to investigate the effect of misclassification
of OUD by ICD-10-CM codes on estimates of the association between OUD and CVD.
For context, we conducted a scoping review of the epidemiological literature on non-acute
opioid use (Kivimaki et al.) and CVD. Data from the University of Kentucky’s Hospital
and Emergency Department inpatient EHR system for 2017 to 2019 were used to conduct
two studies: “Using natural language processing to identify opioid use disorder from EHR
notes,” (2) “Effect of exposure misclassification on the association between opioid use
disorder and cardiovascular disease.” The remainder of this chapter summarizes the major
findings from these studies.
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Chapter Two was a scoping review of the epidemiological literature on nonacute
opioid use and CVD. Twenty-three original articles from the PubMed database were
identified either by key term search or Mesh term search. This review summarized the
current evidence about the association between NOU and five classes of CVD, including
infective endocarditis, coronary heart disease, congestive heart failure, cardiac arrythmia,
and stroke. This review provided evidence that NOU poses a risk not only for cardiac
disorders associated with infections due to needle re-use, such as infective endocarditis,
but may also predispose persons to chronic cardiovascular disorders, including MI and
arrhythmias. This review also demonstrated the dearth of high-quality evidence on the
relationship between NOU and CVD. Many of the identified studies lacked detailed
information on the duration and intensity of opioid exposure and all were retrospectively
conducted. This is understandable, as the challenges to accurate assessment of NOU are
considerable. Innovative approaches to opioid exposure assessment will be required. This
review was published in the Journal of American Heart Association (Singleton et al., 2021).
In Chapter Three we developed a Natural Language Processing (NLP) pipeline for
identifying OUD cases from unstructured clinic notes which no ICD-10-CM codes were
assigned but with strong evidence of OUD in the unstructured clinical notes. We selected
5 types of clinical notes for inclusion in the study: ED triage notes, ED general notes,
History and Physical notes, Addiction Medicine Consult notes, and Discharge Summary
notes. With expert input and literature article reviewing, we developed five dictionaries:
opioid terms, opioid use disorder terms, negation term, special terms of drug use and a
special clinic related to opioid dependence; and 6 parsing rules from the five dictionaries.
Three rules opedrationalized searching for positive mentions of OUD, and three rules

66

pertained to the negation of OUD. Using the Python Natural Language Toolkit, NLTK and
Spacy, we developed an algorithm to carry out rule searches for OUD phrases in the
unstructured clinical notes. All patient visits were classified as OUD or non-OUD based
on information obtained from ICD-10-CM codes and by NLP algorithm. Overall, we
identified 2,332 patients visit as OUD by ICD-10-CM codes or by NLP algorithm applied
to clinical notes. 1902 (6.4%) OUD were identified by NLP and 1,811 (6.1%) identified by
ICD-10-CM codes. 1,381 OUD were identified by both ICD-10-CM and NLP algorithm.
521 patient visits were only identified by NLP algorithm, which was the “hidden” OUD
cases that were identified by NLP algorithm from the unstructured clinical notes but were
missing structured ICD-10-CM. Applying the NLP algorithm, we identified 29% more of
OUD cases compared with the traditional method that only relies on ICD-10-CM diagnosis
codes.
In Chapter Three, we identified an extra group of OUD hospitalizations (521) using
the NLP algorithm in addition to OUD classified by ICD-10-CM codes. In Chapter Four
we carried out an experiment to assess the nature of the misclassification of OUD that
occurs when it is identified using ICD-10-CM codes alone, and the effect of that
misclassification on estimation of the association between OUD and CVD. We conducted
two cross-sectional studies with OUD as the exposure and CVD as the outcome. We used
multivariable Poisson regression models to estimate the prevalence odds ratio for CVD
among patients with OUD, while adjusting for possible confounders. The only difference
between the two studies was the method for ascertaining the patient’s OUD status: by ICD10-CM codes along, or by a combination of ICD-10-CM codes and NLP analysis of clinical
notes. Changes in prevalence rate ratio estimates, when patients with OUD, that was only
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identifiable by NLP analysis of clinical notes, were reclassified from non-OUD to OUD,
were modest. All of the changes were less than 10% different from the estimates that were
based on OUD assessment using ICD-10-CM codes alone. We concluded that weak
associations between OUD and CVD based on ICD-coded administrative hospital data
should be interpreted cautiously.

5.2

Strengths and Limitations
A major strength of this dissertation is that the data were drawn from a large,

clinical cohort with access to all the physician notes, and ICD-10-CM codes. Our team
included a clinical physician who helped to interpret the results and clarify questions about
clinical processes. As we know that NLP provides a powerful tool for text mining of
unstructured notes to produce structured information for research. Using the open-source
programming language, Python, we developed a rule-based NLP algorithm to search the
unstructured clinical notes for mentions of OUD terms and identified an extra group of
OUD cases compared to traditional method that only rely on ICD-10-CM codes.
Using a rule-based NLP algorithm, we identified 2,332 patient visits with evidence
of OUD in unstructured clinical notes. In 2015, Carrell et al. used a rule-based NLP
approach to identify 1,875 (8.5%) patients with problem prescription opioid use (POU) in
a sample of 21,795 patients who were receiving chronic opioid therapy. An ICD-9-CM
code search identified 2,240 (10.1%) patients with POU from the same sample. Our work
extends the findings of ICD-9-CM to ICD-10-CM codes, and extends those receiving
chronic opioid therapy to a broader population of patients not restricted to persons
receiving chronic opioid therapy.
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After we classified patients as having OUD by both ICD-10-CM and by the NLP
algorithm applied to unstructured notes from 2019, we also identified all the patients in
2019 with six type of cardiovascular disease conditions using ICD-10-CM codes: cardiac
arrhythmia, heart failure, acute myocardial infarction (MI), stroke, ischemic heart disease,
and infective endocarditis. We conducted a cross sectional study to estimate the association
between OUD and six cardiovascular diseases (CVD) and conditions. Prevalence of OUD
was ascertained from ICD-10-CM codes alone or ICD-10-CM codes plus NLP algorithm
applied to unstructured notes. Multivariable Poisson regression models, with a robust
variance estimator, were used to estimate prevalence rate ratios to quantify the association
between OUD and CVD prevalence. We also investigated the misclassification of OUD
status on estimates of the association between OUD and CVD.
A limitation of our study is that the patient sample derives from a single hospital
over a period of two years, which is not able to generalized to population level. Moreover,
we used a single year of data (2019) for the study of association of OUD and CVD. This
limits the ability to generalize the findings.
Another limitation is that we included only 5 types of clinical notes. These notes
were selected based on expert opinion and literature review that they were the most likely
to include mentions of OUD. However, the total number of clinical notes available was
much larger. This could account for some cases in which the ICD code search identified a
case of OUD but the NLP algorithm did not.
In addition, we identified the outcome (CVD conditions) using ICD-10-CM codes
alone, introducing potential misclassification of the outcome. Finally, in our crosssectional design in Chapter Four, CVD and OUD were both assessed over a period of one
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year. Our design could be improved by assessing both OUD and CVD using both ICD
codes and NLP in a multi-year, longitudinal sample.

5.3

Future research
To fully understand the association of CVD and OUD using EHR data, a future

study would identify both OUD and CVD from both ICD codes and full sample of clinical
notes, covering multiple sites and years. Also, confounding by smoking, alcohol, and other
variables should be considered. Duration and dose of opioid use should be included in the
study. This kind of study will require access to the data and coordination across facilities,
and a longer time period because of the long latency period for CVD.
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Supplemental Table 2. 1 Specific opioids used in the 23 reviewed studies (cf Table 2.2)
References
Opioid name
Codeine, codeine, dihydrocodeine, dihydrocodone, fentanyl, hydrocodone,
I
hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone,
oxymorphone, propoxyphene, tramadol,
Heroin, oxycodone, oxymorphone
II
Heroin and methadone
III
Morphine, oxycodone, oxycodone-naloxone, hydromorphone, tapentadol,
IV
fentanyl, Buprenorphine
Heroin
V
VI
Diphenoxylate, hydrocodone, hydromorphone, meperidine, morphine sulfate,
oxycodone, pentazocine, tramadol, fentanyl, codeine
VII
Any prescribed opioid: buprenorphine, morphine, meperidine, tramadol,
codeine, dihydrocodeine, propoxyphene, meptazinol
VIII
Hydrocodone bitartrate, codeine phosphate, oxycodone hydrochloride,
propoxyphene hydrochloride, tramadol hydrochloride
IX
Anileridine, codeine phosphate, hydromorphone HCL, morphine HCL,
meperidine HCL, oxycodone HCL, codeine sulfate, codeine phosphate,
acetaminophen-caffeine-codeine, acetaminophen-codeine phosphate,
fentanyl transdermal, acetaminophen-codeine, acetylcalicylic acid-codeinecaffeine, acetylsalicylic acid-codeine, oxycodone-HCL-acetaminophen,
oxycodone HCL-acetylsalicylic acid, morphine HCL, morphine sulfate
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Supplemental Table 3. 1 OUD distribution of ICD-10-CM codes
ICD-10-CM Code for OUD
F11.1
F11.10
F11.11
F11.12, F11.14, F11.18, F11.19
F11.2
F11.20
F11.21
F11.22, F11.23, F11.24, F11.25,
F11.28, F11.29
F11.9
Total

Description
Opioid abuse
Uncomplicated
In remission
With complications
Opioid dependence
Uncomplicated
In remission
With complications
Opioid use
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Counts (%)
692 (38.2%)
58 (3.2%)
11 (0.6%)
632 (35.0%)
24 (1.3%)
229 (12.6%)
165 (9.1%)
1811 (100%)

Supplemental Table 3. 2 Specialized term lists
Specialized term lists
denies alcohol/illicits/tobac
denies drug
denies drug abuse
denies etoh, illicit drugs
denies history of alcohol, tobacco or illegal drug use
denies illicit drug use
denies illict or iv drug use
denies iv drug use
denies smoking, alcohol, illicit drug use
denies smoking, drinking, or using drugs
denies tobacco or illicit drug use
denies tobacco, alcohol, drug use
denies tobacco/etoh/illicit drug use
drug abuse:denies
drugs: denies
illicit drug use: denies
illicits:denies
ivda/intranasal: denies
negative for current tobacco, alcohtextcpol, or recreational
drug use
recreational drugs: denies
no ivda
no intravenous drug abuse
no iv drug use
no intravenous drug user
no iv drug user
no ivdu
no intravenous drug abuse
no iv drug abuse
no iv drug abuse
no iv drug abuser
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Supplemental Table 4. 1 ICD-10-CM codes for CVD conditions
Outcome
ICD-10-CM codes
Atrial Fibrillation DX I48.0, I48.1, 148.11, 148.19, I48.2, 148.20, 148.21, I48.91 (ONLY
first or second
DX on the claim)
Acute Myocardial DX I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4,
Infarction
I21.9, I21.A1,
I21.A9, I22.0, I22.1, I22.2, I22.8, I22.9 (ONLY first or second DX on the
claim)
Stroke/Transient DX G45.0, G45.1, G45.2, G45.8, G45.9, G46.0, G46.1, G46.2, G46.3,
Ischemic Attack G46.4, G46.5,
G46.6, G46.7, G46.8, G97.31, G97.32, I60.00, I60.01, I60.02, I60.10,
I60.11, I60.12,
I60.20, I60.21, I60.22, I60.30, I60.31, I60.32, I60.4, I60.50, I60.51,
I60.52, I60.6,
I60.7, I60.8, I60.9, I61.0, I61.1, I61.2, I61.3, I61.4, I61.5, I61.6, I61.8,
I61.9, I63.00,
I63.02, I63.011, I63.012, I63.013, I63.019, I63.02, I63.031, I63.032,
I63.039, I63.09,
I63.10, I63.111, I63.112, I63.119, I63.12, I63.131, I63.132, I63.139,
I63.19, I63.20,
I63.211, I63.212, I63.213, I63.219, I63.22, I63.231, I63.232, I63.233,
I63.239, I63.29,
I63.30, I63.311, I63.312, I63.313, I63.319, I63.321, I63.322, I63.323,
I63.329,
I63.331, I63.332, I63.333, I63.339, I63.341, I63.342, I63.343, I63.349,
I63.39, I63.40,
I63.411, I63.412, I63.413, I63.419, I63.421, I63.422, I63.423, I63.429,
I63.431,
I63.432, I63.433, I63.439, I63.441, I63.442, I63.443, I63.449, I63.49,
I63.50, I63.511,
I63.512, I63.513, I63.519, I63.521, I63.522, I63.523, I63.529, I63.531,
I63.532,
I63.533, I63.539, I63.541, I63.542, I63.543, I63.549, I63.59, I63.6, I63.8,
I63.9,
I66.01, I66.02, I66.03, I66.09, I66.11, I66.12, I66.13, I66.19, I66.21,
I66.22, I66.23,
I66.29, I66.3, I66.8, I66.9, I67.841, I67.848, I67.89, I97.810, I97.811,
I97.820, I97.821
(any DX on the claim)
EXCLUSION: If any of the qualifying claims have any of the following
codes in any DX
position then EXCLUDE: S01.90XA, S02.0XXA, S02.0XXB, S02.10XA,
S02.10XB,
S02.101A, S02.101B, S02.102A, S02.102B, S02.109A, S02.109B,
S02.11GA, S02.11GB,
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Heart failure

Ischemic heart
disease

S02.11HA, S02.11HB, S02.110A, S02.111A, S02.112A, S02.113A,
S02.110B,
S02.111B, S02.112B, S02.113B, S02.118A, S02.118B, S02.119A,
S02.119B, S02.121A,
S02.121B, S02.121D, S02.121G, S02.121K, S02.121S, S02.122A,
S02.122B, S02.122D,
S02.122G, S02.122K, S02.122S, S02.129A, S02.129B, S02.129D,
S02.129G, S02.129K,
S02.129S, S02.19XA, S02.19XB, S02.2XXA, S02.2XXB, S02.3XXA,
S02.30XA, S02.3XXB,
S02.30XB, S02.31XA, S02.31XB, S02.32XA, S02.32XB, S02.40AA,
S02.40AB, S02.40BA,
S02.40BB, S02.40CA, S02.40CB, S02.40DA, S02.40DB, S02.40EA,
S02.40EB, S02.40FA,
S02.40FB, S02.400A, S02.400B, S02.401A, S02.401B, S02.402A,
S02.402B, S02.411A,
S02.411B, S02.412A, S02.412B, S02.413A, S02.413B, S02.42XA,
S02.42XB, S02.600A,
S02.600B, S02.601A, S02.601B, S02.602A, S02.602B, S02.609A,
S02.609B, S02.61XA,
S02.610A, S02.610B, S02.611A, S02.611B, S02.612A, S02.612B,
S02.62XA, S02.620A,
S02.62XB, S02.620B, S02.621A, S02.621B, S02.622A, S02.622B,
S02.63XA, S02.630A,
S02.63XB, S02.630B, S02.631A, S02.631B, S02.632A, S02.632B,
S02.64XA, S02.640A,
S02.64XB, S02.640B, S02.641A, S02.641B, S02.642A, S02.642B,
S02.65XA, S02.650A,
S02.65XB, S02.650B, S02.651A, S02.651B, S02.652A, S02.652B,
S02.66XA, S02.66XB,
S02.67XA, S02.670A, S02.670B, S02.671A, S02.671B, S02.672A,
S02.672B, S02.69XA,
S02.61XB, S02.62XA, S02.63XA, S02.64XA, S02.65XA, S02.66XA,
S02.67XB, S02.69XB,
S02.8XXA, S02.80XA, S02.8XXB, S02.80XB, S02.81XA, S02.81XB,
S02.82XA, S02.82XB
DX I09.81, I11.0, I13.0, I13.2, I50.1, I50.20, I50.21, I50.22, I50.23,
I50.30, I50.31,
I50.32, I50.33, I50.40, I50.41, I50.42, I50.43, I50.810, I50.811, I50.812,
I50.813,
I50.814, I50.82, I50.83, I50.84, I50.89, I50.9
DX I20.0, I20.1, I20.8, I20.9, I21.01, I21.02, I21.09, I21.11, I21.19,
I21.21, I21.29,
I21.3, I21.4, I21.A1, I21.A9, I22.0, I22.1, I22.2, I22.8, I22.9, I23.0, I23.1,
I23.2, I23.3,
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Infective
endocarditis

I23.4, I23.5, I23.6, I23.7, I23.8, I24.0, I24.1, I24.8, I24.9, I25.10, I25.110,
I25.111,
I25.118, I25.119, I25.2, I25.3, I25.41, I25.42, I25.5, I25.6, I25.700,
I25.701, I25.708,
I25.709, I25.710, I25.711, I25.718, I25.719, I25.720, I25.721, I25.728,
I25.729,
I25.730, I25.731, I25.738, I25.739, I25.750, I25.751, I25.758, I25.759,
I25.760,
I25.761, I25.768, I25.769, I25.790, I25.791, I25.798, I25.799, I25.810,
I25.811,
I25.812, I25.82, I25.83, I25.84, I25.89, I25.9
I33.0, I33.9
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Supplemental Table 4. 2 final model for any CVD outcome, model 1, OUD_ICD

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-1.9049
0.2326
0.6269
1.1826
0.1789
0.041
-0.0778
0.1947
0.0965
0.0959

Adjusted PRR* (95% CI)
1.26 (1.18-1.34)
1.87 (1.74-2.00)
3.26 (3.06-3.47)
1.19 (1.16-1.22)
1.04 (0.99-1.08)
0.92 (0.89-0.95)
1.21 (1.18-1.24)
1.10 (1.07-1.13)
1.10 (1.08-1.11)

Supplemental Table 4. 3 final model for any CVD outcome, model 2, OUD_(ICD+NLP)

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-1.9053
0.1998
0.6249
1.1812
0.1788
0.0421
-0.0771
0.195
0.0961
0.0951
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Adjusted PRR* (95% CI)
1.22 (1.15-1.28)
1.86 (1.74-1.99)
3.25 (3.05-3.47)
1.19 (1.16-1.22)
1.04 (0.99-1.09)
0.92 (0.89-0.95)
1.21 (1.18-1.24)
1.10 (1.07-1.13)
1.09 (1.08-1.11)

Supplemental Table 4. 4 final model for Cardiac arrhythmia, model 1, OUD_ICD

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34 (2)
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-2.1851
0.3434
0.4605
0.9982
0.2343
0.0782
-0.0879
0.1353
0.0333
0.1328

Adjusted PRR* (95% CI)
0.11 (0.10-0.12)
1.40 (1.30-1.52)
1.58 (1.46-1.71)
2.71 (2.52-2.92)
1.26 (1.21-1.31)
1.08 (1.01-1.15)
0.91 (0.87-0.96)
1.14 (1.09-1.19)
1.03 (0.99-1.07)
1.14 (1.11-1.16)

Supplemental Table 4. 5 final model for Cardiac arrhythmia, model 2,
OUD_(ICD+NLP)

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34 (2)
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-2.186
0.289
0.4576
0.9949
0.2345
0.0802
-0.0864
0.1354
0.0325
0.1324
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Adjusted PRR* (95% CI)
0.11 (0.10-0.12)
1.33 (1.24-1.43)
1.58 (1.46-1.71)
2.70 (2.51-2.91)
1.26 (1.21-1.31)
1.08 (1.01-1.15)
0.91 (0.87-0.96)
1.14 (1.09-1.19)
1.03 (0.99-1.07)
1.14 (1.11-1.16)

Supplemental Table 4. 6 final model for MI, model 1, OUD_ICD

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34 (2)
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-5.1376
-0.0619
1.6739
2.3966
0.4273
-0.0364
-0.3474
0.456
-0.0825
0.1477

Adjusted PRR* (95% CI)
0.93 (0.70-1.25)
5.33 (3.63-7.82)
10.9 (7.56-15.9)
1.53 (1.36-1.71)
0.96 (0.80-1.16)
0.70 (0.61-0.81)
1.57 (1.38-1.79)
0.92 (0.81-1.03)
1.15 (1.12-1.19)

Supplemental Table 4. 7 final model for MI, model 2, OUD_(ICD+NLP)

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34 (2)
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-5.1355
-0.0885
1.6751
2.3936
0.4274
-0.0355
-0.3475
0.4554
-0.0822
0.1488
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Adjusted PRR* (95% CI)
0.91 (0.70-1.18)
5.33 (3.63-7.84)
10.9 (7.53-15.9)
1.53 (1.36-1.71)
0.96 (0.80-1.16)
0.70 (0.61-0.81)
1.57 (1.38-1.79)
0.92 (0.81-1.03)
1.16 (1.13-1.19)

Supplemental Table 4. 8 final model for stroke, model 1, OUD_ICD

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34 (2)
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-3.4245
-0.0388
0.8091
1.4382
0.0116
0.1103
-0.3786
0.2453
0.6048
0.0193

Adjusted PRR* (95% CI)
0.96 (0.80-1.15)
2.24 (1.86-2.70)
4.21 (3.52-5.03)
1.01 (0.94-1.08)
1.11 (0.98-1.26)
0.68 (0.63-0.74)
1.27 (1.18-1.38)
1.83 (1.68-1.98)
1.01 (0.98-1.05)

Supplemental Table 4. 9 final model for stroke, model 2, OUD_(ICD+NLP)

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34 (2)
Sex: Male vs Female
Race: White vs. Other
Non-Hispanic vs others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-3.4189
-0.1286
0.8098
1.429
0.0123
0.113
-0.3786
0.2436
0.6051
0.0222
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Adjusted PRR* (95% CI)
0.87 (0.74-1.03)
2.24 (1.86-2.70)
4.17 (3.49-4.98)
1.01 (0.94-1.08)
1.11 (0.98-1.26)
0.68 (0.63-0.74)
1.27 (1.17-1.38)
1.83 (1.68-1.98)
1.02 (0.98-1.05)

Supplemental Table 4. 10 final model for heart failure, model 1, OUD_ICD

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. other
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-3.7558
0.143
1.5364
2.5906
0.1972
-0.2089
-0.1148
0.6685
-1.1844
0.165

Adjusted PRR* (95% CI)
1.15 (0.98-1.35)
4.64 (3.79-5.68)
13.3 (11.0-16.1)
1.21 (1.14-1.29)
0.81 (0.73-0.89)
0.89 (0.82-0.96)
1.95 (1.82-2.08)
0.30 (0.28-0.32)
1.17 (1.14-1.21)

Supplemental Table 4. 11 final model for heart failure, model 2, OUD_(ICD+NLP)

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-3.7604
0.1783
1.5338
2.5955
0.197
-0.2097
-0.115
0.6697
-1.1852
0.1634
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Adjusted PRR* (95% CI)
1.19 (1.04-1.36)
4.63 (3.79-5.66)
13.4 (11.0-16.2)
1.21 (1.14-1.29)
0.81 (0.73-0.88)
0.89 (0.82-0.96)
1.95 (1.83-2.08)
0.30 (0.28-0.32)
1.17 (1.14-1.21)

Supplemental Table 4. 12 final model for ISCHEMICHD, model 1, OUD_ICD

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34
Sex: Male vs. Female
Race: White vs. Other
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-5.6587
-0.2211
2.7935
3.8904
0.4225
0.2366
-0.0165
0.4342
0.0158
0.1041

Adjusted PRR* (95% CI)
0.80 (0.68-0.93)
16.3 (11.1-23.9)
48.9 (33.4-71.4)
1.52 (1.45-1.60)
1.26 (1.15-1.39)
0.98 (0.92-1.05)
1.54 (1.46-1.62)
1.01 (0.96-1.06)
1.10 (1.08-1.12)

Supplemental Table 4. 13 final model for ISCHEMICHD, model 2, OUD_(ICD+NLP)

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34
Sex: Male vs Female
Race: White vs. Other
Non-Hispanic vs others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-5.6592
-0.1661
2.7951
3.893
0.4222
0.2355
-0.0172
0.434
0.016
0.1043
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Adjusted PRR* (95% CI)
0.84 (0.74-0.96)
16.3 (11.1-24.0)
49.0 (33.5-71.6)
1.52 (1.45-1.60)
1.26 (1.15-1.39)
0.98 (0.92-1.04)
1.54 (1.46-1.62)
1.01 (0.96-1.06)
1.10 (1.08-1.13)

Supplemental Table 4. 14 final model for IE, model 1, OUD_ICD

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34
>= 55 vs. 18-34
Sex: Male vs Female
Non-Hispanic vs others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-6.5242
2.9287
0.0396
-1.4034
0.0311
-1.1903
-0.6684
0.5439
-0.2464

Adjusted PRR* (95% CI)
18.7 (6.95-50.3)
1.04 (0.41-2.62)
0.24 (0.05-1.20)
1.03 (0.43-2.43)
0.30 (0.12-0.72)
0.51 (0.05-4.66)
1.72 (0.70-4.19)
0.78 (0.34-1.77)

Supplemental Table 4. 15 final model for IE, model 2, OUD_(ICD+NLP)

Intercept
OUD vs. Non-OUD
35-54 vs. 18-34 (Keller
et al.)
>= 55 vs. 18-34
Sex: Male vs. Female
Non-Hispanic vs. others
Diabetes
Hypertension
Visit counts
* PRR: Prevalence rate ratio

Coefficient Estimate
-6.5919
2.9326
0.0328
-1.4034
-0.0232
-1.1904
-0.6501
0.5323
-0.2736
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Adjusted PRR* (95% CI)
18.7 (6.80-51.8)
1.03 (0.40-2.63)
0.24 (0.05-1.14)
0.97 (0.40-2.33)
0.30 (0.12-0.73)
0.52 (0.05-4.68)
1.70 (0.70-4.12)
0.76 (0.33-1.72)

* Discharge Summary, History and Physical, ED General, ED Triage, Addiction Medicine
Consult
Supplemental Figure 2. 1 Diagram of applying NLP algorithm to testing data set
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